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PROGRAM 
 
 
TUESDAY, March 16—7:30 PM 
 
 
SESSION 1 UPSTREAM OF PTEN 
 
Chairperson: R. Parsons, Columbia University, New York, New York 
 
 
Examining the PI3K isoform dependence of murine tumors driven 
by PTEN loss 
Thomas Roberts. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts. 
 
  
Integration of PI3K scaffold and catalytic functions in health and 
disease 
Emilio Hirsch. 
Presenter affiliation: University of Torino, Torino,  Italy. 
 
 
 
1 
  
Insights into the oncogenic effects of PIK3CA mutations from the 
structure of Phosphoinsitide-3-kinase 
C.-H. Huang, D. Mandelker, Ignacia Echeverria, B. Vogelstein, Oleg 
Schmidt-Kittler, S.B. Gabelli, L. M. Amzel. 
Presenter affiliation: Johns Hopkins University School of Medicine, 
Baltimore, Maryland; Johns Hopkins Kimmel Cancer Center, Baltimore, 
Maryland. 
 
 
 
 
 
 
2 
  
Overlapping and distinct oncogenic properties of the E545K and 
H1047R PIK3CA mutations 
Elias E. Stratikopoulos, Matthias Szabolcs, Ramon Parsons, Argiris 
Efstratiadis. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
 
3 
  
Context-dependent functions of PI3K signaling in brain 
Xiaoyan Zhu, Nader  Chalhoub, Lionel M. Chow, Sherri L. Rankin, 
David W. Ellison, Suzanne J. Baker. 
Presenter affiliation: St. Jude Children’s Research Hospital, Memphis, 
Tennessee. 
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 vi 
WEDNESDAY, March 17—9:00 AM 
 
 
SESSION 2 DOWNSTREAM OF PTEN 
 
Chairperson: L. Trotman, Cold Spring Harbor Laboratory, New York 
 
  
Akt Isoform-specific signaling in breast cancer cell invasive 
migration 
Alex Toker, Rebecca Y. Chin. 
Presenter affiliation: Beth Israel Deaconess Medical Center, Boston, 
Massachusetts. 
 
 
 
 
5 
  
Transcriptional repressor NFIL3 modulates the PI3K/PTEN/FOXO 
pathway to attenuate FOXO-mediated gene expression 
Megan E. Keniry, Maria M. Pires, Ramon E. Parsons. 
Presenter affiliation: Columbia University Medical Center, New York, 
New York. 
 
 
 
 
6 
  
Coordinated regulation of glucose-dependent survival by 
FOXO3A and S6K1 downstream of PTEN/AKT 
Preeti Tandon, Shikha Khatri, Jennifer F. Barger, Catherine A. Gallo, 
Ashley Allemang, David R. Plas. 
Presenter affiliation: University of Cincinnati, Cincinnati, Ohio. 
 
 
 
 
7 
  
DNA damage-dependent function of AKT is maintained 
independently of PI3K signaling elements in C. ELEGANS 
Andrew J. Perrin, W. Brent Derry. 
Presenter affiliation: The Hospital for Sick Children, Toronto, Canada. 
 
 
 
8 
  
PHLiPPing the switch in lipid second messenger signaling 
Alexandra C. Newton. 
Presenter affiliation: University of California, San Diego, La Jolla, 
California. 
 
 
 
9 
  
The role of PTEN and PHLPP in prostate cancer metastasis 
Muhan Chen, Christopher Pratt, Martha Zeeman, Barry S. Taylor, 
Danielle M. Grace, Audrey O'Neill, Kato Mamoru, Michael Zhang, 
Carlos CordonCardo, Charles L. Sawyers, William Gerald, Alexandra 
C. Newton, Brett S. Carver, Lloyd C. Trotman. 
Presenter affiliation: Cold Spring Harbor Laboratory, New York. 
 
 
 
 
 
10 
  
 vii 
Tumour suppression by PTEN requires the activation of the PKR-
eIF2a phosphorylation pathway. 
Zineb Mounir, Jothi Latha Krishnamoorthy, Robertson P. Gavin, 
Randal J. Kaufman, Maria-Magdalena Georgescu, Antonis E. 
Koromilas. 
Presenter affiliation: Lady Davis Institute for Medical Research and 
McGill University, Montreal, Canada. 
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WEDNESDAY, March 17—2:00 PM 
 
 
SESSION 3 POSTER SESSION I 
 
  
The PTEN-Daxx complex is regulated by acetylation and 
phosphorylation 
Jorge A. Benitez, Webster K. Cavenee, Frank B. Furnari. 
Presenter affiliation: Ludwig Institute for Cancer Research, University 
of California-San Diego, La Jolla, California. 
 
 
 
 
12 
  
Disruption of an inhibitory interface with p85 is responsible for 
the oncogenic potential of p110ß 
Hashem A. Dbouk, Jonathan M. Backer. 
Presenter affiliation: Albert Einstein College of Medicine, Bronx, New 
York. 
 
 
 
 
13 
  
mTORC2 is regulated through multi-site phosphorylation of a 
regulatory domain within Rictor 
Christian C. Dibble, John M. Asara, Brendan D. Manning. 
Presenter affiliation: Harvard School of Public Health, Boston, 
Massachusetts. 
 
 
 
 
14 
  
Separation of two forms of clathrin light chain B that differently 
affect a type 1-like protein phosphatase from microtubules 
Akira Hiraga. 
Presenter affiliation: Institute of Development, Aging and Cancer, 
Tohoku, Sendai, Japan. 
 
 
 
 
15 
  
The role of P-Rex2a in tumorigenesis through inhibition of PTEN 
Cindy Hodakoski, Barry Fine, Susan Koujak, Benjamin Hopkins, Tao 
Su, Ramon Parsons. 
Presenter affiliation: Columbia University Medical Center, New York, 
New York. 
 
 
 
 
16 
  
 viii 
PTEN plays a pivotal role in retinal neurogenesis by supporting 
Notch signaling 
Hong Seok Jo, Kyung Hwa Kang, Jaeho Lee, Cheol O. Joe, Greg 
Lemke, Jin Woo Kim. 
Presenter affiliation: Korea Advanced Institute of Science and 
Technology, Daejeon, South Korea. 
 
 
 
 
 
17 
  
Role of a novel interaction between PTEN and drebrin at central 
nervous system synapses 
Patricia Kreis, Michiel Van Diepen, Maddy Parsons, Nick Leslie, Britta 
Eickholt. 
Presenter affiliation: King's College London, London, United Kingdom. 
 
 
 
 
18 
  
Coordinated regulation of dictyostelium AGC kinases AKT and 
PKBR1 by PI3K/PTEN, TORC2 and PDK1—Lessons from ancient 
organism 
Xin-Hua Liao, Jonathan Buggey, Alan R. Kimmel. 
Presenter affiliation: NIDDK, National Institutes of Health, Bethesda, 
Maryland. 
 
 
 
 
 
19 
  
Regulation of RUNX3 by PI3K/AKT in colorectal cancer 
Anthony C. Lim, Kosei Ito, Yoshiaki Ito. 
Presenter affiliation: Cancer Science Institute of Singapore, Singapore, 
Singapore. 
 
 
 
20 
  
Phosphatidylinositol 3’ kinase (PI3K) oncogenic mutations 
increase invasiveness and drug resistance in breast epithelial 
cells 
Fabiana C. Morales, Yiling Lu, Gordon B. Mills. 
Presenter affiliation: University of Texas MD Anderson Cancer Center, 
Houston, Texas. 
 
 
 
 
 
21 
  
CD95-induced signaling in glioma downstream of PI3K 
Marcin Teodorczyk, Ignacio Sancho-Martinez, Sachin Kumar, Ana 
Martin-Villalba. 
Presenter affiliation: German Cancer Research Centre, Heidelberg, 
Germany. 
 
 
 
 
22 
  
Evidence for the significance of PTEN’s protein phosphatase 
activity in tumor suppression 
Laura Spinelli, Priyanka Tibarewal, Lindsay Davidson, Helene 
Maccario, Nevin M. Perera, Charles P. Downes, Nick R. Leslie. 
Presenter affiliation: University of Dundee, Dundee, United Kingdom. 
 
 
 
 
23 
  
 ix 
PTEN in whole chromosome instability 
Janine H. van Ree, Karthik B. Jeganathan, Jan M. van Deursen. 
Presenter affiliation: Mayo Clinic College of Medicine, Rochester, 
Minnesota. 
 
 
 
24 
  
Stimulation of its negative regulator PHLPP provides a feedback 
loop on Akt that is preferentially lost in glioblastoma 
Noel Warfel, Matt Niederst, Alexandra C. Newton. 
Presenter affiliation: University of California, San Diego, La Jolla, 
California. 
 
 
 
 
25 
  
Recurrent interstitial genomic deletion of the human PTEN gene 
are facilitated by flanking microhomologies 
Maisa Yoshimoto, Andrew Evans, Kanishka Sircar, Tarek Bismar, Julia 
Williams, Paulo Nuin, Jeremy A. Squire. 
Presenter affiliation: Queen's University, Kingston, Canada. 
 
 
 
 
26 
  
FoxO1 is essential for the regulation of pluripotency in human 
embryonic stem cells 
Xin Zhang, Safak Yalcin, Marion Kennedy, Rani Sellers, Markus 
Landthaler, Thomas Tuschl, Gordon Keller, Saghi Ghaffari. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
 
 
 
 
 
27 
  
Functional analysis of the protein phosphatase activity of PTEN 
Xiaoqun C. Zhang. 
Presenter affiliation: Cold Spring Harbor Laboratory, Cold Spring 
Harbor, New York. 
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WEDNESDAY, March 17—4:30 PM 
 
Wine and Cheese Party 
 
 
 x 
WEDNESDAY, March 17—7:30 PM 
  
 
SESSION 4 PTEN REGULATION 
 
Chairperson: P. Devreotes, Johns Hopkins University School of  
  Medicine, Baltimore, Maryland 
 
  
The cell’s compass—Signaling networks that mediate chemotaxis 
in eucaryotic cells 
Peter N. Devreotes, Yulia Artemenko, Jane Borleis, Huaqing Cai, 
Jonathan Franca-Koh, Yoichiro Kamimura, Yu Long, Meghdad Rahdar, 
Kristen Swaney, Michelle Tang. 
Presenter affiliation: Johns Hopkins University School of Medicine, 
Baltimore, Maryland. 
 
 
 
 
 
 
29 
  
MyosinV-dependent transport of PTEN regulates PI3K signalling 
and neuronal morphogenesis 
Britta J. Eickholt, Tomas Perez, Michiel T. van Diepen, Maddy 
Parsons, Nick Leslie. 
Presenter affiliation: King’s College London, London, United Kingdom. 
 
 
 
 
30 
  
The regulation and mechanisms of action of the PTEN enzyme 
Nick R. Leslie. 
Presenter affiliation: University of Dundee, Dundee, United Kingdom. 
 
 
31 
  
Dynamic nuclear localization of Pten in zebrafish 
Petra W. van Duijn, Suma Choorapoikayil, Jeroen den Hertog. 
Presenter affiliation: Hubrecht Institute, Utrecht, Netherlands. 
 
 
32 
  
Alteration of PTEN signaling as a driving force for cancer 
Ramon Parsons. 
Presenter affiliation: Columbia University, New York, New York. 
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 xi 
THURSDAY, March 18—9:00 AM 
 
 
SESSION 5 DEVELOPMENT AND DISEASE MODELS 
 
Chairperson: H. Wu, University of California, Los Angeles 
 
  
Mouse models as translational tools to discover treatments for 
autism spectrum disorders—Focus on rapamycin 
Luis F. Parada. 
Presenter affiliation: University of Texas Southwestern Medical Center, 
Dallas, Texas. 
 
 
 
 
34 
  
Tuberous sclerosis—Recent results on genes, pathways, human 
disease, and mouse models 
David J. Kwiatkowski. 
Presenter affiliation: Brigham and Women's Hospital, Boston, 
Massachusetts. 
 
 
 
 
35 
  
Akt2 is required for specific glycolytic isozyme expression and 
cancer progression in PTEN-deficient mouse liver steatohepatitis 
Ganna Panasyuk, Catherine Espeillac, Céline Chauvin, Ivan 
Nemazanyy, Morris J. Birnbaum, Jean-Ehrland Ricci, Mario Pende. 
Presenter affiliation: INSERM, Paris, France; Université Paris 
Descartes, Paris, France. 
 
 
 
 
 
36 
  
Pten pathway alterations are associated with bladder tumor 
progression 
Carlos Cordon-Cardo. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
 
37 
  
PTEN, stem cells and tumorigenesis 
Hong Wu, Wei  Guo, Suzanne Schubbert. 
Presenter affiliation: UCLA, Los Angeles, California. 
 
 
38 
  
Function and regulation of the PTEN tumor suppressor gene 
Pier-Paolo Pandolfi. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
 
 
 
 xii 
THURSDAY, March 18—2:00 PM 
 
 
SESSION 6 POSTER SESSION II 
 
  
Lovastatin inhibits EGFR dimerization and AKT activation in 
squamous cell carcinoma cells 
Jim Dimitroulakos, Tong T. Zhao. 
Presenter affiliation: Ottawa Hospital Research Institute, Ottawa, 
Canada. 
 
 
 
 
39 
  
Biallelic inactivation of TSC1 in radial Glia results in mTOR 
pathway activation 
David M. Feliciano, Tiffany Su, Angelique Bordey. 
Presenter affiliation: Yale University, New Haven, Connecticut. 
 
 
 
40 
  
An important role for PTEN tyrosine phosphorylation in 
glioblastoma pathogenesis and responses to treatment 
Tim R. Fenton, Daisuke Kuga, Akio Iwanami, Claudio Ponte de 
Albuquerque, Robert M. Bachoo, Ronald A. Depinho, C David James, 
Huilin Zhou, Suely K. Marie, Paul S. Mischel, Webster K. Cavenee, 
Frank B. Furnari. 
Presenter affiliation: Ludwig Insitute for Cancer Research, La Jolla, 
California. 
 
 
 
 
 
 
 
41 
  
PTEN and osteoblastogenesis 
Anyonya R. Guntur, Martina I. Reinhold, Michael C. Naski. 
Presenter affiliation: University of Texas Health Sciences Center, San 
Antonio, Texas. 
 
 
 
42 
  
Genetic and preclinical interrogation of a genetically engineered 
mouse model of small cell lung carcinoma 
Patricia Hamilton, Jason Long, Anthony Lima, Rafael Molina, Hani 
Bou-Reslan, Tim Cao, Michelle Nannini, Richard Carano, Li Li, William 
Forrest, Suzana Couto, Leisa Johnson. 
Presenter affiliation: Genentech, South San Francisco, California. 
 
 
 
 
 
43 
  
The dual PI3K/mTOR inhibitor NVP-BEZ235 induces cell death via 
the extrinsic apoptosis pathway 
Irmgard Hofmann, Saskia M. Brachmann, Christian Schnell, Heidi 
Lane, Christine Fritsch, Carlos Garcia-Echeverria, Michel Maira. 
Presenter affiliation: NIBR, Basel, Switzerland. 
 
 
 
 
44 
  
 xiii 
Pten and P53 control self-renewal ability and differentiation 
potential of prostate epithelial stem/progenitor cells 
Paul G. Hynes, Wassim G. Abou-Kheir, Philip L. Martin, Kathleen 
Kelly. 
Presenter affiliation: NCI, National Institutes of Health, Bethesda, 
Maryland. 
 
 
 
 
 
45 
  
Phospho-proteomics and mass-action modeling identify optimal 
drug combinations in signaling networks 
Sergio Iadevaia, Yiling Lu, Fabiana C. Morales, Gordon B. Mills, 
Prahlad T. Ram. 
Presenter affiliation: MD Anderson Cancer Center, Houston, Texas. 
 
 
 
 
46 
  
The PI3K pathway in a mouse model for invasive lobular 
carcinoma of the breast 
Sjoerd Klarenbeek, Tanya Braumuller, Ingrid van der Heijden, Gilles 
Doumont, Jos Jonkers. 
Presenter affiliation: The Netherlands Cancer Institute, Amsterdam, 
Netherlands. 
 
 
 
 
 
47 
  
Acinar cell neoplasia following conditional inactivation of Apc 
and Pten in the mouse salivary gland—Activation of mTOR 
signaling in human acinic cell carcinoma 
Charlotta Lindvall, Cassandra Diegel, Nicole Evans, Adel El-Naggar, 
Kathleen R. Cho, Bart O. Williams. 
Presenter affiliation: Van Andel Research Institute, Grand Rapids, 
Michigan. 
 
 
 
 
 
 
48 
  
The role of Pten in murine prostate development 
Isabel Lokody, Amanda Swain. 
Presenter affiliation: Institute of Cancer Research, London, United 
Kingdom. 
 
 
 
49 
  
Pro-senescence therapy for cancer and The Co-Clinical Trial 
Project 
Caterina Nardella, Andrea Alimonti, Hui-Kuan Lin, Pier Paolo Pandolfi. 
Presenter affiliation: Beth Israel Deaconess Medical Center, Harvard 
Medical School, Boston, Massachusetts. 
 
 
 
 
50 
  
The core protein of HCV 3a triggers PTEN downregulation in 
hepatocytes—Role in HCV-mediated steatosis and insulin 
resistance. 
Marion Peyrou, Sophie Clément, Manlio Vinciguerra, Andrea Sanchez, 
David Suter, Kevin Guilloux, Stephanie Pascarella, Karl-Heinz Krause, 
Laura Rubbia-Brandt, Francesco Negro, Michelangelo Foti. 
Presenter affiliation: University of Geneva, Geneva, Switzerland. 
 
 
 
 
 
 
51 
 xiv 
Combined deletion of Pten, Trp53 and Rb1 induced astrocytomas 
within and outside of proliferative niches in the mature brain 
Sherri L. Rankin, Lionel M. Chow, Raelene Endersby, Xiaoyan Zhu, 
Junyuan Zhang, Chunxu Qu, David W. Ellison, Suzanne J. Baker. 
Presenter affiliation: St Jude Children’s Research Hospital, Memphis, 
Tennessee. 
 
 
 
 
 
52 
  
Expansion of hepatic tumor progenitor cells in Pten deficient 
mice requires liver injury 
Vivian Galicia, Lina He, Gary Kanel, Christopher Vandryes, Ni Zeng, 
Jennifer-Ann Bayan, C. Bart Rountree, Kasper Wang, Morris 
Birnbaum, Bangyan Stiles. 
Presenter affiliation: University of Southern California, Los Angeles, 
California. 
 
 
 
 
 
 
53 
  
Bioluminescence imaging captures the expression of p21Waf1/Cip1 
in living mice 
Kelsey L. Tinkum, Lynn White, Jinwu Sun, David Piwnica-Worms, 
Helen Piwnica-Worms. 
Presenter affiliation: Washington University School of Medicine, St. 
Louis, Missouri. 
 
 
 
 
 
54 
  
Oxidative stress-mediated amplification of AKT/mTOR signaling 
pathway leads to myeloproliferative syndrome in FoxO3-null 
mice—A role for Lnk adaptor protein 
Safak Yalcin, Xin Zhang, Dragan Marinkovic, Wei Tong, Sathish K. 
Mungamuri, Saghi Ghaffari. 
Presenter affiliation: Mount Sinai School of Medicine, New York, New 
York. 
 
 
 
 
 
 
55 
  
Mammalian target of rapamycin regulates cell differentiation 
through the STAT3-p63-Jagged-Notch cascade 
Jianhui Ma, Huangxuan Shen, Xinxin Chen, Haiyong Peng, Qian Sun, 
Xiaojun Zha, Fang Wang, Ying Wang, Shu Zhang, Lizi Wu, David J. 
Kwiatkowski, Hongbing Zhang. 
Presenter affiliation: Chinese Academy of Medical Sciences and 
Peking Union Medical College, Beijing, China. 
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 xv 
THURSDAY, March 18—7:30 PM 
 
 
SESSION 7 mTORC1 AND INTERSECTING PATHWAYS 
 
Chairperson: B. Manning, Harvard School of Public Health, Boston,  
  Massachusetts 
 
  
The LKB1/AMPK tumor suppressor pathway coordinates cell 
growth and metabolism 
Reuben J. Shaw. 
Presenter affiliation: Salk Institute for Biological Studies, La Jolla, 
California. 
 
 
 
 
57 
  
Activation of a metabolic gene regulatory network downstream of 
mTORC1 
Katrin Duvel, Jessica L. Yecies, Suchithra Menon, Clary B. Clish, Leon 
O. Murphy, Brendan D. Manning. 
Presenter affiliation: Harvard School of Public Health, Boston, 
Massachusetts. 
 
 
 
 
 
58 
  
Integration of amino acid and glucose signaling in mTOR 
complex 1 (mTORC1)-dependent regulation of cell growth and 
survival 
John Blenis, Andrew Y. Choo, Sang Gyun Kim, Greg R. Hoffman, Neil 
Kubica, Sarah J. Mahoney. 
Presenter affiliation: Harvard Medical School, Boston, Massachusetts. 
 
 
 
 
 
59 
  
The late endosome is essential for mTORC1 signaling 
Rory J. Flinn, Ying Yan, Sumanta Goswami, Peter J. Parker, Jonathan 
M. Backer. 
Presenter affiliation: Albert Einstein College of Medicine, Bronx, New 
York. 
 
 
 
 
60 
  
FoxOs serve as an energy stress checkpoint and suppress 
mTORC1-mediated renal cancer development 
Boyi Gan, Carol Lim, Gerald Chu, Sujun Hua, Zhihu Ding, Jian Hu, 
William G. Kaelin Jr., Sabina Signoretti, Ronald A. DePinho. 
Presenter affiliation: Dana-Farber Cancer Institute, Boston, 
Massachusetts. 
 
 
 
 
 
61 
  
mTOR and the control of growth 
David M. Sabatini. 
Presenter affiliation: Whitehead Institute, Cambridge, Massachusetts. 
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 xvi 
FRIDAY, March 19—9:00 AM 
 
 
SESSION 8 THERAPY AND CANCER MODELS 
 
Chairperson: J. Engelman, Massachusetts General Hospital, Boston 
 
  
Forkhead proteins in insulin action 
Domenico Accili. 
Presenter affiliation: Columbia University, New York, New York. 
 
 
63 
  
Systems biology approach to personalized medicine 
Gordon B. Mills. 
Presenter affiliation: University of Texas M.D. Anderson Cancer 
Center, Houston, Texas. 
 
 
 
64 
  
Feedback and redundancy in PI3K activated pathways in cancer—
Therapeutic implications 
Neal Rosen. 
Presenter affiliation: Memorial Sloan-Kettering Cancer Center, New 
York, New York. 
 
  
Using mechansitic insights into PI3K regulation to identify 
therapeutic strategies to treat cancer 
Jeffrey Engelman. 
Presenter affiliation: Massachusetts General Hospital, Boston, 
Massachusetts. 
 
  
The mTOR pathway in cancer: mechanisms and therapeutic 
promise 
Karen Cichowski. 
Presenter affiliation: BWH/Harvard Medical School, Boston, 
Massachusetts. 
 
 
 
 
65 
  
Preclinical evidence supporting combination partners for NVP-
BEZ235 breast cancer trials 
Saskia M. Brachmann, Irmgard Hofmann, Susan Wee, Carlos Garcia-
Echeverria, Michel S. Maira. 
Presenter affiliation: NIBR, Basel, Switzerland. 
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 xvii 
FRIDAY, March 19—6:00 PM 
 
CONCERT 
Grace Auditorium 
 
Ran Dank, piano 
 
Pianist Ran Dank was awarded the Sander Buchman Memorial First Prize in the 
2008-09 Young Concert Artists International Auditions and makes his debut on 
December 14 this season in the Young Concert Artists Series at Merkin Concert 
Hall in New York, sponsored by the Jerome L. Greene Foundation Prize. At the 
Auditions, he was awarded many special prizes: the John Browning Memorial 
Prize, the Slomovic Orchestra Soloist Prize, the Albany Symphony Prize (GA), 
the Embassy Series Prize for a concert at an Embassy in Washington DC, and 
the Saint Vincent College Bronder Prize for Piano (PA). During the 2009-10 
season, Mr. Dank will be heard at the University of Florida, the International 
Keyboard Institute and Festival at the Mannes College in New York, at the 
Seattle Chamber Music Festival, for the Patrons for Young Artists series (NY), at 
the Port Washington Library (NY), for Vanguard Concerts (OH), at the Jewish 
Community Alliance (FL), and for the Xavier University Piano Series (OH). 
 
Mr. Dank won First Prize in the 2008 Hilton Head International Piano Competition 
and was awarded the 2006 Gina Bachauer Scholarship at the Juilliard School. In 
2007, he won top prizes in the Sydney International Piano Competition in 
Australia, leading to an extensive Australian tour including a concerto 
performance with the Sydney Symphony, and the Cleveland International 
Competition, bringing him an appearance with the Cleveland Orchestra under the 
baton of Jahja Ling. Mr. Dank has performed as soloist with the Juilliard 
Orchestra as winner of the Concerto Competition, and in his native Israel with the 
symphony orchestras of Jerusalem, Rishon Lezion and Raanana. Festival 
appearances have included the Chopin Festival in Warsaw, the Israel Festival, 
and return engagements to Finland’s Mäntta Festival for Virtuoso Pianists. 
 
Mr. Dank was born in Israel in 1982 and started piano lessons at the age of 
seven. He received his Bachelor’s degree from the Rubin Academy of Music at 
Tel Aviv University, where he studied with Emanuel Krasovsky. He is the 
recipient of grants from the America-Israel Cultural Foundation. Mr. Dank has a 
Master’s degree from the Juilliard School where he worked with Emanuel Ax and 
Joseph Kalichstein (both YCA “Alumni”). Mr. Dank also earned an Artist Diploma 
from the Juilliard School in 2009, working with Robert McDonald.  
 
 
FRIDAY, March 19 
 
BANQUET 
 
Cocktails  7:00 PM Dinner  7:45 PM 
 xviii 
SATURDAY, March 20—9:00 AM 
 
 
SESSION 9 AGING, METABOLISM AND CANCER 
 
Chairperson: A. Brunet, Stanford University, California 
 
  
Oncogenic signaling in the class I PI3K pathway 
Jonathan R. Hart, Li Zhao, Petra Hillmann, Petra Pavlickova, Minghao 
Sun, Lynn Ueno, Peter K. Vogt. 
Presenter affiliation: The Scripps Research Institute, La Jolla, 
California. 
 
 
 
 
67 
  
Role of FOXO transcription factors in aging 
Anne Brunet. 
Presenter affiliation: Stanford University, Stanford, California. 
 
 
68 
  
CRTC-1—A novel Calcineuin and AMPK target for lifespan 
extension in C. elegans 
William Mair, Ianessa Morantte, Reuben Shaw, Andrew Dillin. 
Presenter affiliation: Howard Hughes Medical Institute and Glenn 
Center for Aging Research, The Salk Institute for Biological Studies, La 
Jolla, California. 
 
 
 
 
 
69 
  
Protection from metabolic damage and increased longevity by 
PTEN 
Ana Ortega-Molina, Alejo Efeyan, Mulero Francisca, Manuel Serrano. 
Presenter affiliation: Fundacion CNIO, Madrid, Spain. 
 
 
 
70 
  
PDZ-RhoGEF regulates adipose tissue development via 
insulin/IGF-1 signaling 
Ying-Ju Jang, Lily Zhou, Nicole Liadis, Christine K. Ng, Zenyu Hao, 
Scott Pownall, Vuk Stambolic, Tak W. Mak. 
Presenter affiliation: University of Toronto, Canada. 
 
 
 
 
71 
  
PI3K and cancer metabolism 
Lewis Cantley. 
Presenter affiliation: Beth Israel Deaconess Medical Center, Boston, 
Massachusetts. 
 
 
 
 xix 
     AUTHOR INDEX 
 
 
Abou-Kheir, Wassim G., 45 
Accili, Domenico, 63 
Alimonti, Andrea, 50 
Allemang, Ashley, 7 
Amzel, L. M., 2 
Artemenko, Yulia, 29 
Asara, John M., 14 
 
Bachoo, Robert M., 41 
Backer, Jonathan M., 13, 60 
Baker, Suzanne J., 4, 52 
Barger, Jennifer F., 7 
Bayan, Jennifer-Ann, 53 
Benitez, Jorge A., 12 
Birnbaum, Morris, 36, 53 
Bismar, Tarek, 26 
Blenis, John, 59 
Bordey, Angelique, 40 
Borleis, Jane, 29 
Bou-Reslan, Hani, 43 
Brachmann, Saskia M., 44, 66 
Braumuller, Tanya, 47 
Brunet, Anne, 68 
Buggey, Jonathan, 19 
 
Cai, Huaqing, 29 
Cao, Tim, 43 
Carano, Richard, 43 
Carver, Brett S., 10 
Cavenee, Webster K., 12, 41 
Chalhoub, Nader, 4 
Chauvin, Céline, 36 
Chen, Muhan, 10 
Chen, Xinxin, 56 
Chin, Rebecca Y., 5 
Cho, Kathleen R., 48 
Choo, Andrew Y., 59 
Choorapoikayil, Suma, 32 
Chow, Lionel M., 4, 52 
Chu, Gerald, 61 
Cichowski, Karen, 65 
Clément, Sophie, 51 
Clish, Clary B., 58 
CordonCardo, Carlos, 10, 37 
 
 
Couto, Suzana, 43 
 
Davidson, Lindsay, 23 
Dbouk, Hashem A., 13 
den Hertog, Jeroen, 32 
DePinho, Ronald A., 41, 61 
Derry, W. Brent, 8 
Devreotes, Peter N., 29 
Dibble, Christian C., 14 
Diegel, Cassandra, 48 
Dillin, Andrew, 69 
Dimitroulakos, Jim, 39 
Ding, Zhihu, 61 
Doumont, Gilles, 47 
Downes, Charles P., 23 
Duvel, Katrin, 58 
 
Echeverria, Ignacia, 2 
Efeyan, Alejo, 70 
Efstratiadis, Argiris, 3 
Eickholt, Britta, 18, 30 
Ellison, David W., 4, 52 
El-Naggar, Adel, 48 
Endersby, Raelene, 52 
Espeillac, Catherine, 36 
Evans, Andrew, 26 
Evans, Nicole, 48 
 
Feliciano, David M., 40 
Fenton, Tim R., 41 
Fine, Barry, 16 
Flinn, Rory J., 60 
Forrest, William, 43 
Foti, Michelangelo, 51 
Franca-Koh, Jonathan, 29 
Francisca, Mulero, 70 
Fritsch, Christine, 44 
Furnari, Frank B., 12, 41 
 
Gabelli, S.B., 2 
Galicia, Vivian, 53 
Gallo, Catherine A., 7 
Gan, Boyi, 61 
Garcia-Echeverria, Carlos, 44, 66 
 xx 
Gavin, Robertson P., 11 
Georgescu, Maria-Magdalena,  
   11 
Gerald, William, 10 
Ghaffari, Saghi, 27, 55 
Goswami, Sumanta, 60 
Grace, Danielle M., 10 
Guilloux, Kevin, 51 
Guntur, Anyonya R., 42 
Guo, Wei, 38 
 
Hamilton, Patricia, 43 
Hao, Zenyu, 71 
Hart, Jonathan R., 67 
He, Lina, 53 
Hillmann, Petra, 67 
Hiraga, Akira, 15 
Hirsch, Emilio, 1 
Hodakoski, Cindy, 16 
Hoffman, Greg R., 59 
Hofmann, Irmgard, 44, 66 
Hopkins, Benjamin, 16 
Hu, Jian, 61 
Hua, Sujun, 61 
Huang, C.-H., 2 
Hynes, Paul G., 45 
 
Iadevaia, Sergio, 46 
Ito, Kosei, 20 
Ito, Yoshiaki, 20 
Iwanami, Akio, 41 
 
James, C David, 41 
Jang, Ying-Ju, 71 
Jeganathan, Karthik B., 24 
Jo, Hong Seok, 17 
Joe, Cheol O., 17 
Johnson, Leisa, 43 
Jonkers, Jos, 47 
 
Kaelin Jr., William G., 61 
Kamimura, Yoichiro, 29 
Kanel, Gary, 53 
Kang, Kyung Hwa, 17 
Kaufman, Randal J., 11 
Keller, Gordon, 27 
Kelly, Kathleen, 45 
Keniry, Megan E., 6 
Kennedy, Marion, 27 
Khatri, Shikha, 7 
Kim, Jin Woo, 17 
Kim, Sang Gyun, 59 
Kimmel, Alan R., 19 
Klarenbeek, Sjoerd, 47 
Koromilas, Antonis E., 11 
Koujak, Susan, 16 
Krause, Karl-Heinz, 51 
Kreis, Patricia, 18 
Krishnamoorthy, Jothi Latha, 11 
Kubica, Neil, 59 
Kuga, Daisuke, 41 
Kumar, Sachin, 22 
Kwiatkowski, David J., 35, 56 
 
Landthaler, Markus, 27 
Lane, Heidi, 44 
Lee, Jaeho, 17 
Lemke, Greg, 17 
Leslie, Nick R., 18, 23, 30, 31 
Li, Li, 43 
Liadis, Nicole, 71 
Liao, Xin-Hua, 19 
Lim, Anthony C., 20 
Lim, Carol, 61 
Lima, Anthony, 43 
Lin, Hui-Kuan, 50 
Lindvall, Charlotta, 48 
Lokody, Isabel, 49 
Long, Jason, 43 
Long, Yu, 29 
Lu, Yiling, 21, 46 
 
Ma, Jianhui, 56 
Maccario, Helene, 23 
Mahoney, Sarah J., 59 
Mair, William, 69 
Maira, Michel, 44, 66 
Mak, Tak W., 71 
Mamoru, Kato, 10 
Mandelker, D., 2 
Manning, Brendan D., 14, 58 
Marie, Suely K., 41 
Marinkovic, Dragan, 55 
Martin, Philip L., 45 
 xxi 
Martin-Villalba, Ana, 22 
Menon, Suchithra, 58 
Mills, Gordon B., 21, 46, 64 
Mischel, Paul S., 41 
Molina, Rafael, 43 
Morales, Fabiana C., 21, 46 
Morantte, Ianessa, 69 
Mounir, Zineb, 11 
Mungamuri, Sathish K., 55 
Murphy, Leon O., 58 
 
Nannini, Michelle, 43 
Nardella, Caterina, 50 
Naski, Michael C., 42 
Negro, Francesco, 51 
Nemazanyy, Ivan, 36 
Newton, Alexandra C., 9, 10, 25 
Ng, Christine K., 71 
Niederst, Matt, 25 
Nuin, Paulo, 26 
 
O'Neill, Audrey, 10 
Ortega-Molina, Ana, 70 
 
Panasyuk, Ganna, 36 
Pandolfi, Pier Paolo, 50 
Parada, Luis F., 34 
Parker, Peter J., 60 
Parsons, Maddy, 18, 30 
Parsons, Ramon, 3, 6, 16, 33 
Pascarella, Stephanie, 51 
Pavlickova, Petra, 67 
Pende, Mario, 36 
Peng, Haiyong, 56 
Perera, Nevin M., 23 
Perez, Tomas, 30 
Perrin, Andrew J., 8 
Peyrou, Marion, 51 
Pires, Maria M., 6 
Piwnica-Worms, David, 54 
Piwnica-Worms, Helen, 54 
Plas, David R., 7 
Ponte de Albuquerque, Claudio,  
   41 
Pownall, Scott, 71 
Pratt, Christopher, 10 
 
Qu, Chunxu, 52 
 
Rahdar, Meghdad, 29 
Ram, Prahlad T., 46 
Rankin, Sherri L., 4, 52 
Reinhold, Martina I., 42 
Ricci, Jean-Ehrland, 36 
Rountree, C. Bart, 53 
Rubbia-Brandt, Laura, 51 
 
Sabatini, David M., 62 
Sanchez, Andrea, 51 
Sancho-Martinez, Ignacio, 22 
Sawyers, Charles L., 10 
Schmidt-Kittler, Oleg, 2 
Schnell, Christian, 44 
Schubbert, Suzanne, 38 
Sellers, Rani, 27 
Serrano, Manuel, 70 
Shaw, Reuben, 57, 69 
Shen, Huangxuan, 56 
Signoretti, Sabina, 61 
Sircar, Kanishka, 26 
Spinelli, Laura, 23 
Squire, Jeremy A., 26 
Stambolic, Vuk, 71 
Stiles, Bangyan, 53 
Stratikopoulos, Elias E., 3 
Su, Tao, 16 
Su, Tiffany, 40 
Sun, Jinwu, 54 
Sun, Minghao, 67 
Sun, Qian, 56 
Suter, David, 51 
Swain, Amanda, 49 
Swaney, Kristen, 29 
Szabolcs, Matthias, 3 
 
Tandon, Preeti, 7 
Tang, Michelle, 29 
Taylor, Barry S., 10 
Teodorczyk, Marcin, 22 
Tibarewal, Priyanka, 23 
Tinkum, Kelsey L., 54 
Toker, Alex, 5 
Tong, Wei, 55 
Trotman, Lloyd C., 10 
 xxii 
Tuschl, Thomas, 27 
 
Ueno, Lynn, 67 
 
van der Heijden, Ingrid, 47 
van Deursen, Jan M., 24 
Van Diepen, Michiel, 18, 30 
van Duijn, Petra W., 32 
van Ree, Janine H., 24 
Vandryes, Christopher, 53 
Vinciguerra, Manlio, 51 
Vogelstein, B., 2 
Vogt, Peter K., 67 
 
Wang, Fang, 56 
Wang, Kasper, 53 
Wang, Ying, 56 
Warfel, Noel, 25 
Wee, Susan, 66 
White, Lynn, 54 
Williams, Bart O., 48 
Williams, Julia, 26 
Wu, Hong, 38 
Wu, Lizi, 56 
Yalcin, Safak, 27, 55 
Yan, Ying, 60 
Yecies, Jessica L., 58 
Yoshimoto, Maisa, 26 
 
Zeeman, Martha, 10 
Zeng, Ni, 53 
Zha, Xiaojun, 56 
Zhang, Hongbing, 56 
Zhang, Junyuan, 52 
Zhang, Michael, 10 
Zhang, Shu, 56 
Zhang, Xiaoqun C., 28 
Zhang, Xin, 27, 55 
Zhao, Li, 67 
Zhao, Tong T., 39 
Zhou, Huilin, 41 
Zhou, Lily, 71 
Zhu, Xiaoyan, 4, 52 
 1 
INTEGRATION OF PI3K SCAFFOLD AND CATALYTIC FUNCTIONS 
IN HEALTH AND DISEASE 
 
Emilio Hirsch  
University of Torino, Molecular Biotechnology Center, Via Nizza 52, 
Torino, 10125, Italy 
 
Phosphoinositide 3-kinases (PI3K) are key players in receptor-mediated 
signal transduction and play a role in a large variety of biological processes. 
PI3K consist of heterodimers of a 110 kD catalytic (p110) as well as a 
regulatory/adapter subunit and are required for the production of a 
membrane bound phosphorylated lipid (PIP3) that acts as a secondary 
messenger molecule. Class I p110s (p110α, β, γ and δ) share significant 
homology but studies using genetically engineered mice show that they all 
play non-redundant roles. While these reports recently provided support for 
PI3K as promising drug targets they also unexpectedly revealed that these 
proteins not only work as kinases but also as scaffolds for protein-protein 
interactions. For example, we showed that p110β catalytic activity is 
required for male fertility and for Erbb2 driven mammary gland cancer 
development. On the other hand, loss of p110β blocks endocytosis and 
results in reduced fibroblast proliferation and embryonic lethality. 
Similarly, p110γ plays a crucial role in the mounting of inflammatory 
reactions as well as in leukemia but it is also part of a multiprotein complex 
that controls cAMP levels and cardiac contractility. Indeed, we found that 
p110γ is a scaffold protein that mediates a reciprocal control between 
cAMP and PIP3 signaling. These data not only support the view of PI3K as 
drug targets for ATP binding site competitors but also for more 
sophisticated protein-protein interaction inhibitors. 
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INSIGHTS INTO THE ONCOGENIC EFFECTS OF PIK3CA 
MUTATIONS FROM THE STRUCTURE OF PHOSPHOINSITIDE-3-
KINASE 
 
C.-H. Huang1,2, D. Mandelker1,2, Ignacia Echeverria1,2, B. Vogelstein1,2, 
Oleg Schmidt-Kittler1,2, S.B. Gabelli1,2, L. M. Amzel1,2  
1Johns Hopkins University School of Medicine, Department of Biophysics 
and Biophysical Chemistry, 725 N. Wolfe Street, Baltimore, MD, 21205, 
2Johns Hopkins Kimmel Cancer Center, Ludwig Center for Cancer Genetics 
and Therapeutics, Howard Hughes Medical Institute, Baltimore, MD, 21231 
 
Phosphatidylinositide-3-kinases (PI3K) initiate a number of signaling 
pathways by recruiting other kinases, such as Akt, to the plasma membrane. 
One of the isoforms, PI3Kα, is an oncogene frequently mutated in several 
cancer types. These mutations increase PI3K kinase activity, leading to 
increased cell survival, cell motility, cell metabolism, and cell cycle 
progression. The structure of the complex between the catalytic subunit of 
PI3Kα, p110α, and a portion of its regulatory subunit, p85α reveals that the 
majority of the oncogenic mutations occur at the interfaces between p110 
domains and between p110 and p85 domains. At these positions, mutations 
disrupt interactions resulting in changes in the kinase domain that may 
increase enzymatic activity. The structure also suggests that interaction with 
the membrane is mediated by a region of the heterodimer that includes one 
of the p85 domains (iSH2). The structure of the most common oncogenic 
mutation, H1047R, shows differences in p110 with the wild-type that 
indicate that this mutation may activate the enzyme by increasing its 
interaction with the cellular membrane. These findings may provide novel 
structural loci for the design of isoform-specific, mutant-specific new anti-
cancer drugs. 
 3 
OVERLAPPING AND DISTINCT ONCOGENIC PROPERTIES OF THE 
E545K AND H1047R PIK3CA MUTATIONS. 
 
Elias E Stratikopoulos1,4, Matthias Szabolcs2, Ramon Parsons1,2,3, Argiris 
Efstratiadis4  
1Columbia University, Institute for Cancer Genetics, 1130 St Nicholas 
Avenue, New York, NY, 10032, 2Columbia University, Department of 
Pathology, 622 West 168th Street, New York, NY, 10032, 3Columbia 
University, Department of Medicine, 630 West 168th Street, New York, 
NY, 10032, 4 Columbia University, Department of Genetics and 
Development, 1150 St Nicholas Avenue, New York, NY, 10032 
 
One of the signaling pathways that is centrally involved in mammary 
tumorigenesis is the phosphoinositide 3’-kinase (PI3K) pathway. 
Importantly, it was recently established that PIK3CA, the gene encoding the 
catalytic subunit of PI3K, often harbors heterozygous gain-of-function 
missense mutations in human malignancies, including ~30% of breast 
cancer cases. The majority of the mutations in PIK3CA cluster in two 
regions, within the helical and kinase domains (HD & KD). The codons 
most frequently affected are E545K and H1047R (“hot-spots”) in exons 9 
and 20, respectively. Both types of these mutations increase the kinase 
activity of the enzyme, upregulate the downstream AKT pathway, and 
stimulate cell transformation and tumorigenesis. Despite the similarities in 
the effects of the two hotspot mutations, there is growing evidence that they 
are not equivalent. To analyze the action of PIK3CA hotspot mutations in 
mammary tumorigenesis we have generated mouse models carrying either 
one of these two gain-of-function “knock-in” mutations on conditionally-
expressed alleles. Both mutations are embryonic lethal but when they are 
activated postnatally either globally or specifically in mammary epithelial 
cells display differential physiological functions and oncogenic properties. 
PIK3CA mutations cooperate with c-Myc overexpression, leading to rapid 
formation of multifocal mammary tumors which show increased protease 
activity and metastasize to the lung soon after their establishment. 
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CONTEXT-DEPENDENT FUNCTIONS OF PI3K SIGNALING IN 
BRAIN 
 
Xiaoyan Zhu1, Nader Chalhoub1, Lionel M Chow1, Sherri L Rankin1, David 
W Ellison2, Suzanne J Baker1  
1St. Jude Children's Research Hospital, Department of Developmental 
Neurobiology, 262 Danny Thomas Place, Memphis, TN, 38105, 2St. Jude 
Children's Research Hospital, Department of Pathology, 262 Danny 
Thomas Place, Memphis, TN, 38105 
 
PTEN plays an essential role in development, homeostatic maintenance and 
tumor suppression in the mammalian brain. Although the effectors in the 
PI3K/PTEN pathway are ubiquitously expressed, there are cell-type and 
context-dependent variations in pathway regulation that likely underlie 
differences in how abnormal PI3K signaling contributes to pathological 
conditions arising from different cell types. Conditional deletion of key 
effectors in the PI3K pathway including Pten and Pdk1 revealed cell type-
specific differences in regulation of PI3K signaling in brain. Loss of 
function mutations of PTEN and oncogenic mutations of PIK3CA both 
occur in glioblastoma, the most common and most aggressive malignant 
brain tumor. To determine the physiological consequences of activating the 
PI3K pathway through these different effectors, we used in vivo conditional 
induction of Pten deletion or Pik3ca E545K mutation to define their roles in 
normal and tumorigenic growth regulation in brain. 
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AKT ISOFORM-SPECIFIC SIGNALING IN BREAST CANCER CELL 
INVASIVE MIGRATION  
 
Alex Toker, Rebecca Y Chin  
Beth Israel Deaconess Medical Center, Pathology, 330 Brookline Avenue, 
Boston, MA, 02215 
 
Akt/PKB (protein kinase B) is a proto-oncogene that plays critical roles in 
cell survival, proliferation and metabolism. There are three mammalian Akt 
isoforms: Akt1, Akt2 and Akt3. They share a high degree of amino acid 
similarity and are activated by similar mechanisms. The current paradigm is 
that all three Akt isoforms promote cancer cell survival and growth. 
Interestingly, recent studies from our laboratory have shown that Akt1 
inhibits breast cancer cell migration and invasion. Conversely, Akt2 has 
been shown to promote breast cancer cell migration. We therefore seek to 
test the hypothesis that Akt isoforms regulate breast cancer cell invasive 
migration in a distinct manner, and investigate the mechanistic basis for this 
selectivity. Current experiments are undertaken to identify novel substrates 
of Akt1 and Akt2, which modulate cell motility, with a combination of 
shRNA and phospho-proteomic approaches. shRNAs specific to Akt1 or 
Akt2 have been generated and delivered into human breast cancer cells by 
lentiviral vectors. Using an antibody that recognizes phosphorylated 
serine/threonine residues contained within a consensus Akt motif 
(RXRXXS/T), we showed that palladin, a component of actin-containing 
microfilaments, is phosphorylated at serine 507 by Akt1 but not Akt2. 
Downregulation of palladin using RNA interference enhances migration 
and invasion of breast cancer cells and induces abnormal branching 
morphogenesis in 3D cultures, indicative of an anti-migratory function for 
palladin. Importantly, palladin is required for Akt1-mediated inhibition of 
breast cancer cell migration, whereby the migratory effect induced by 
palladin silencing is reversed by wild-type but not a S507A mutant. Finally, 
palladin phosphorylation by Akt1 is functionally required for bundling F-
actin and maintaining an organized actin cytoskeleton network in cells. 
These findings identify palladin as an Akt1-specific substrate that regulates 
cell motility and further provide a molecular mechanism that accounts for 
the functional distinction between Akt isoforms in breast cancer cell 
migration. 
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TRANSCRIPTIONAL REPRESSOR NFIL3 MODULATES THE 
PI3K/PTEN/FOXO PATHWAY TO ATTENUATE FOXO-MEDIATED 
GENE EXPRESSION 
 
Megan E Keniry1, Maria M Pires1, Ramon E Parsons1,2,3  
1Columbia University Medical Center, Institute for Cancer Genetics and 
Herbert Irving Comprehensive Cancer Center, 1130 St. Nicholas Avenue, 
New York, NY, 10032, 2Columbia University Medical Center, Department 
of Pathology, 630 W. 168th Street, New York, NY, 10032, 3Columbia 
University Medical Center, Department of Medicine, 630 W. 168th Street, 
New York, NY, 10032 
 
PI3K/PTEN signaling is frequently altered in cancer. Unraveling 
PI3K/PTEN pathway architecture will facilitate the identification of novel 
biomarkers and drug targets to better treat cancer. We isolated the pro-
survival NFIL3 transcription factor in a reporter screen designed to identify 
novel pathway regulators. We found that NFIL3 integrated into PI3K/PTEN 
signaling at the transcriptional level by regulating a broad repertoire of 
FOXO-induced genes. NFIL3 associated with the promoters of FOXO-
induced genes and co-repressed transcription with HDAC2. Loss and gain 
of function experiments revealed that NFIL3 is a critical regulator of 
apoptosis in cancer cells. NFIL3 and HDAC2 were found to be highly 
expressed in cancers that confer poor prognosis, suggesting that HDAC 
inhibition may be an effective therapy for these cancers. NFIL3 expression 
was associated with poor prognosis in breast cancer. Thus, NFIL3 is a new 
transcriptional modulator of PI3K/PTEN/FOXO signaling that could 
potentially serve as a novel pathway biomarker/drug target. 
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COORDINATED REGULATION OF GLUCOSE-DEPENDENT 
SURVIVAL BY FOXO3A AND S6K1 DOWNSTREAM OF PTEN/AKT 
 
Preeti Tandon, Shikha Khatri, Jennifer F Barger, Catherine A Gallo, Ashley 
Allemang, David R Plas  
University of Cincinnati, Cancer and Cell Biology, 3125 Eden Avenue, 
Cincinnati, OH, 45267 
 
PTEN inactivation triggers Akt-dependent apoptosis resistance that 
contributes to both oncogenesis and resistance to chemotherapeutics. We 
have shown that Akt-induced glucose metabolism is a required element for 
apoptosis resistance in PTEN-deficient cells. The downstream signaling 
elements that mediate Akt-dependent increases in glycolysis are not fully 
characterized. Our results show that both the FOXO-family transcription 
factors and the TSC-mTORC1-S6K1 pathways are critical for glucose-
dependent cell survival mediated by Akt. FOXO3a knockdown is sufficient 
to induce glycolysis associated with cell survival. Increased glycolysis in 
FOXO3a-deficient cells is due to decreased transcription of TSC1, leading 
to elevated S6K1 activity. Reexpression of TSC1 or rapamycin treatment 
are sufficient to reestablish basal rates of glycolysis in FOXO3a-knockdown 
cells. In PTEN-deficient cells, S6K1-knockdown reduces glycolysis and 
enforces apoptosis sensitivity. Restoring glycolysis by expression of HIF-1α 
is sufficient to reactivate apoptosis resistance in S6K1-deficient cells. 
Together the data reveal that crosstalk between the FOXO and TSC-
mTORC1-S6K1 pathways downstream of Akt is critical for establishing the 
glycolytic metabolic program that supports Akt-dependent survival. 
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DNA DAMAGE-DEPENDENT FUNCTION OF AKT IS MAINTAINED 
INDEPENDENTLY OF PI3K SIGNALING ELEMENTS IN 
CAENORHABDITIS ELEGANS 
 
Andrew J Perrin, W Brent Derry 
The Hospital for Sick Children, Program in Developmental and Stem Cell 
Biology, 101 College Street, Toronto, M5G 1L7, Canada 
 
The roundworm Caenorhabditis elegans possesses a single, conserved 
phosphatidylinositol 3-kinase (PI3K) signaling pathway that regulates 
somatic developmental decisions and lifespan through the Insulin-like 
receptor tyrosine kinase (RTK) DAF-2, the class I PI3K AGE-1 and the 
PDK1 homologue PDK-1. This pathway ultimately controls the action of 
Akt homologues on the forkhead transcription factor DAF-16. We recently 
demonstrated that the C. elegans Akt orthologue akt-1 also negatively 
regulates the DNA damage-dependent apoptosis of worm germ cells by 
interfering with activation of the key transcription factor CEP-1, a sole 
homologue of p53 in the worm. Because upstream regulation by RTK/PI3K 
signaling is known to couple with downstream Akt kinase activity, we 
hypothesized that the worm daf-2/age-1/pdk-1 pathway would function 
upstream of akt-1/Akt in response to DNA damage. Surprisingly, this was 
not the case. Instead, loss-of-function (lf) mutants in daf-2/RTK, age-
1/PI3K, and pdk-1/PDK1 were all extremely resistant to DNA damage, 
while a gain-of-function (gf) mutant in pdk-1 was hypersensitive, 
confirming that, unlike akt-1/Akt, RTK/PI3K signaling components promote 
damage-induced germ cell apoptosis in C. elegans. Subsequent genetic 
analysis demonstrated that lf mutations in both daf-2/RTK and pdk-1/PDK1 
were epistatic to akt-1/Akt, and thus, daf-2/RTK and pdk-1/PDK1 do not 
function upstream of akt-1/Akt in response to damage. In addition, while 
AKT-1/Akt functions upstream of CEP-1/p53 and is able to control its 
damage-dependent transcriptional function in vivo, loss of neither daf-
2/RTK nor pdk-1/PDK1 hindered transcriptional function of CEP-1/p53 at 
the egl-1/BH3-only target gene promoter. Therefore, daf-2/RTK and pdk-
1/PDK1 function independently of akt-1/Akt and cep-1/p53 to promote 
damage-induced germ cell death. It appears that daf-2/RTK, pdk-1/PDK1, 
and cep-1/p53 co-operate from mutually exclusive pathways to drive germ 
cell death since a pdk-1(gf) mutation cannot revert the daf-2 phenotype, yet 
still requires cep-1/p53 to kill. That RTK/PI3K signaling can be separated 
from Akt function in the worm suggests that akt-1/Akt may be regulated in a 
novel manner in response to DNA damage, and that a single PI3K signaling 
pathway can be re-arranged to suit a variety of situations in vivo. This 
shuffling of RTK/PI3K signaling modules in C. elegans may represent a 
more general example of how signaling pathways acquire functional 
resilience in the absence of evolutionary complexity. 
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PHLiPPing THE SWITCH IN LIPID SECOND MESSENGER 
SIGNALING 
 
Alexandra C Newton 
University of California, San Diego, Pharmacology, 9500 Gilman Drive, La 
Jolla, CA, 92093-0721 
 
The Ser/Thr specific-phosphatase PHLPP (PH domain leucine-rich repeat 
protein phosphatase) provides the brakes to signaling in both the PI3 kinase 
and diacylglycerol pathways. The two isoforms of this recently discovered 
family, PHLPP1 and PHLPP2, control the amplitude and duration of 
signaling by two distinct mechanisms: 1] direct dephosphorylation of Akt 
and PKC at the hydrophobic phosphorylation motif, a C-terminal 
phosphorylation switch that controls the activity of these kinases, and 2] 
control of cellular levels of growth factor receptors by regulation of their 
mRNA levels. This contribution focuses on the cellular function and 
regulation of PHLPP. 
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THE ROLE OF PTEN AND PHLPP IN PROSTATE CANCER 
METASTASIS 
 
Lloyd C Trotman1, Muhan Chen1, Christopher Pratt1, Martha Zeeman1, 
Barry S. Taylor2, Danielle M. Grace1, Audrey O’Neill3, Kato Mamoru1, 
Michael Zhang1, Carlos Cordon-Cardo4, Charles L. Sawyers2,5, William 
Gerald2, Alexandra C. Newton3, Brett S. Carver2 
1Cold Spring Harbor Lab, Cancer Center, One Bungtown Road, Cold 
Spring Harbor, NY, 11724 
2Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering 
Cancer Center, New York, New York, USA. 
3University of California San Diego, 9500 Gilman Dr., La Jolla, CA 92093, 
USA. 
4 Department of Pathology, Columbia University, New York, New York, 
USA. 
5 Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer 
Center, New York, New York, USA 
 
Modeling partial and complete Pten-loss in mice, has revealed that this 
pathway controls prostate cancer onset, progression, and outcome. While 
these findings underscore the role of Pten regulation in cancer, we have 
recently uncovered an equally critical role for signal termination, as Pp2a-
mediated Akt inactivation in the nucleus is essential and sufficient for 
prevention of colon and prostate cancer, even after partial loss of Pten. To 
broaden our understanding of signal termination in cancer, we are studying 
the second class of known phosphatases of Akt, namely the Phlpp genes. To 
this end, we follow prostate tumorigenesis in cohorts of Phlpp knockout 
mice, which have a normal or hyperactive PI 3-K pathway by virtue of 
heterozygosity for Pten. 
 
Our analysis reveals that Phlpp-loss on its own initiates tumorigenesis in 
prostate and other tissues and that it strongly cooperates with partial loss of 
Pten. To demonstrate its role in human prostate cancer we will present 
results from our study on the genome wide analysis of several hundred 
patient biopsies, banked at Memorial Sloan Kettering Cancer Center.  
 11 
TUMOUR SUPPRESSION BY PTEN REQUIRES THE ACTIVATION 
OF THE PKR-EIF2Α PHOSPHORYLATION PATHWAY.  
 
Zineb Mounir1,2, Jothi Latha Krishnamoorthy1, Robertson P Gavin3, Randal 
J Kaufman4, Maria-Magdalena Georgescu5, Antonis E Koromilas1,6  
 
1Lady Davis Institute for Medical Research, Jewish General Hospital, 3999 
Cote Ste-Catherine, Montreal, H3T 1E2, Canada, 2McGill University, 
Division of Experimental Medicine, Faculty of Medicine, 845 Sherbrooke 
Street, Montreal, H3A 2T5, Canada, 3The Pennsylvania State University 
College of Medicine, Department of Pharmacology , 500 University Drive, 
Hershey, PA, 17033, 4 University of Michigan Medical Center, Biological 
Chemistry and Internal Medicine and the Howard Hughes Medical Institute 
, 4570 MSRB, Ann Arbor, MI, 48109, 5University of Texas MD Anderson 
Cancer Center, Department of Molecular Genetics, 1515 Holcombe 
Boulevard, Houston, TX, 77030, 6McGill University, Department of 
Oncology, Faculty of Medicine, 845, Sherbrooke St. W, Montreal, H3A 
2T5, Canada 
 
Inhibition of protein synthesis by phosphorylation of the α subunit of 
eukaryotic translation initiation factor 2 (eIF2) at Ser51 occurs due to the 
activation of a family of kinases in response to various forms of stress. 
Although some aspects of the phosphorylation of eIF2α are cytoprotective, 
phosphorylation of eIF2α by RNA-dependent protein kinase (PKR) is 
largely proapoptotic and tumor suppressing in nature. Phosphatase and 
tensin homolog deleted from chromosome 10 (PTEN) is a tumor suppressor 
protein that is mutated or deleted in various human cancers. The function of 
PTEN is mediated through phosphatase-dependent and -independent 
pathways. We demonstrate that the eIF2α phosphorylation pathway acts 
downstream of PTEN. Inactivation of PTEN in human melanoma cells 
reduced the extent of phosphorylation of eIF2α, whereas reconstitution of 
PTEN-null human glioblastoma or prostate cancer cells with either wild 
type PTEN or phosphatase-defective mutants of PTEN induced the activity 
of PKR and the phosphorylation of eIF2α. The antiproliferative and 
proapoptotic effects of PTEN were substantially compromised in mouse 
embryonic fibroblasts that lacked PKR or contained a phosphorylation-
defective allele of eIF2α. Induction of the pathway leading to 
phosphorylation of eIF2α required the presence of an intact PDZ-binding 
motif in PTEN. These findings establish a link between tumor suppression 
by PTEN and inhibition of protein synthesis independently of the inhibition 
of phosphoinositide 3’-kinase signaling. 
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THE PTEN-DAXX COMPLEX IS REGULATED BY ACETYLATION 
AND PHOSPHORYLATION 
 
Jorge A Benitez, Webster K Cavenee, Frank B Furnari  
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Post-translational modifications of PTEN, such as phosphorylation and 
acetylation, which are associated with its conformational changes (“closed” 
to “open”) and stability, have been associated with PTEN tumor suppressor 
function. We have previously reported that phosphorylation at threonine 
366 (T366) in the C-terminal region of PTEN, regulates cellular 
proliferation and transformation independently of its lipid phosphatase 
activity and by physical interaction suppresses the transformation potential 
of MSP58 (human microspherule protein 1) (Okumura et al., 2005), which 
is highly expressed in GBM samples and glioma cells (Lin et al., 2008). 
Because little is known about the tumor suppressor function of T366 
phospho-PTEN, we analyzed its interactions with others proteins. We found 
that one of these PTEN-associated proteins that binds in this region is Daxx 
(death domain-associated protein). Here, we show that physical interaction 
with Daxx occurs through PTEN amino acids 186-202, which is the same 
region involved in its interaction with PCAF (p300/CBP-associated factor), 
a histone acetyltransferase that regulates the acetylation of Lys 125 and Lys 
128 of PTEN. After DNA damage in glioma cells the acetylation of PTEN 
is increased and the PTEN-Daxx complex is destabilized, suggesting a 
potential role for Daxx in regulating PTEN-acetylation. In addition, the 
PTEN- Daxx interaction was T366-phosphorylation dependent, as 
demonstrated by reduced association with PTEN mutated to alanine at this 
position. Finally, the PTEN-Daxx interaction in cells occurs even in the 
absence of p53, but the interaction is stronger when either p53 or pten are 
mutated. We hypothesize that PTEN phosphorylation and acetylation may 
be mediating the assembly of diverse complexes and thus playing a 
regulatory role in its tumor suppressor function. 
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DISRUPTION OF AN INHIBITORY INTERFACE WITH p85 IS 
RESPONSIBLE FOR THE ONCOGENIC POTENTIAL OF p110β 
 
Hashem A Dbouk, Jonathan M Backer  
Albert Einstein College of Medicine, Molecular Pharmacology, 1300 
Morris Park Ave, Bronx, NY, 10461 
 
Class I PI3Ks signal downstream of RTKs and GPCRs, and have been 
implicated in tumorigenesis. In contrast to p110α, whose oncogenic 
potential requires its mutational activation, other p110 isoforms can induce 
transformation by over-expression of the wild type enzyme. Sequence 
alignment reveals that the residue analogous to N345 in p110α is K342 in 
p110β. This difference makes wild type p110β analogous to an oncogenic 
mutant p110α (N345K). In p110α, N345 in the C2 domain forms hydrogen 
bonds with D560 and N564 in the iSH2 domain of p85, and mutations of 
p110 or p85 that disrupt this interface lead to increased basal activity and 
transformation. We now show that p110β exhibits a higher basal activity 
with wild type p85 than p110α, and is not further activated by a mutation of 
p85 that disrupts the C2-iSH2 domain interface. Similar results were seen in 
soft agar transformation assays, where p110β was similar to p110α N345K 
in transformation potential. The regulation of p110β by p85 was restored by 
a K342N mutation of p110β, which showed decreased activity in vitro, and 
decreased Akt activation and transformation in NIH3T3 cells. Moreover, 
unlike wild type p110β, p110β-K342N is differentially regulated by wild 
type versus oncogenic p85 mutants. This study shows that the higher basal 
p110β activity and its transforming potential are due in part to disruption of 
an inhibitory interface with the iSH2 domain of p85. 
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The serine/threonine protein kinase mammalian target of rapamycin 
(mTOR) acts within two physically and functionally distinct complexes 
(mTORC1 and mTORC2) to control cell growth, proliferation, survival, and 
metabolism. While there has been great progress in understanding the 
regulation of mTORC1, much less is known about the signaling 
mechanisms that regulate mTORC2. To better understand mTORC2 
regulation, we characterized the phosphorylation events on its essential core 
component Rictor. Interestingly, most of the 21 phosphorylation sites we 
identified on Rictor are conserved throughout vertebrates and cluster within 
an approximately 400 a.a. region in the C-terminal half of the protein. We 
propose that this region has evolved as a regulatory domain that allows 
multiple signaling pathways to control mTORC2 through post-translational 
modification of Rictor. We have recently found that deletion of this 
regulatory domain yields a Rictor mutant that, as part of mTORC2, induces 
a dramatic increase in phosphorylation of both growth factor-dependent 
(e.g., Akt-S473) and -independent (e.g., Akt-T450) substrates of mTORC2. 
These results suggest that this domain of Rictor plays a net negative role in 
the regulation of mTORC2. We have identified one specific 
phosphorylation site (T1135) within this region that acts to negatively 
regulate mTORC2. Rictor-T1135 is a new substrate of S6K1 that is 
phosphorylated in response to growth factors and amino acids downstream 
of mTORC1. Expression of a non-phosphorylatable mutant (Rictor-
T1135A) in cells moderately increases mTORC2-dependent 
phosphorylation of Akt-S473 in response to insulin. However, mutation of 
this site does not affect the in vitro kinase activity of mTORC2. Therefore, 
phosphorylation of Rictor-T1135 by S6K1 constitutes a new negative 
feedback mechanism affecting Akt activation. We are currently determining 
the molecular mechanisms by which the regulatory domain of Rictor 
controls mTORC2 signaling to its downstream substrates and exploring 
potential input from PI3K and PTEN. We will report on the most up-to-date 
findings from these efforts. 
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PTEN controls a variety of intracellular processes, hydrolyzing 3-phosphate 
of phosphatidylinositol 3,4,5-triphosphate. The class 1 and the class 2 
phosphoinositide 3-kinase can antagonize (the latter when activated by 
clathrin) PTEN and may function in pathways involving clathrin and MT, 
respectively, through downstream kinases Akt and GSK3 and through the 
action on clathrin assembly and the linkage of clathrin and MTs. These 
pathways may be found in NMDA receptor internalization, CLUT4 
translocation, neurosecretion and cellular entry and propagation of viruses. 
We reported that clathrin light chain b (CLb) could affect potently and 
selectively a type-1-like protein phosphatase (PP) that was cosedimented 
with brain microtubules (MTs) and thus termed MT-PP1. Since the known 
binding motif for PP1 is not found in CLb, the interaction between CLb and 
MT-PP1 may form a novel regulatory mechanism for PP and also contribute 
to functional linkage of clathrin and MTs. Thus, small but new information 
below of the interaction may help further analysis of PTEN downstream 
pathways. The CLb preparation reported previously was purified from the 
post-MT supernatant containing 25 % glycerol and comprised two forms of 
CLb of 29 kDa and 32 kDa (hereafter called respectively CLb29 and 
CLb32). In the absence of glycerol, CLb32 was coisolated with the clathrin 
fraction but CLb29 remained in the cytosol fraction. CLb29 and CLb32 
were each purified using the procedures we reported for purification of 29 
kDa and 32 kDa CLb from the post-MT supernatant. CLb29 affected MT-
PP1 with an EC50 of about 1 nM. CLb32 also affected MT-PP1 but with an 
EC50 of about 500 nM. Interestingly, both CLb affected MT-PP1 several-
fold more strongly than PP1 molecules purified from skeletal muscle. 
CLb29 was similarly purified from the cytosol independent of whether the 
brain extract was incubated at 37 ˚C for MT assembly and whether it 
contained 0.5 NaCl.  
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The tumor suppressor PTEN (phosphatase and tensin homologue deleted on 
chromosome 10) was discovered through the mapping of homozygous 
deletions on human chromosome 10q23 due to its frequent loss of 
heterozygosity in human tumors. PTEN, a lipid and protein phosphatase, 
acts as a tumor suppressor by inhibiting PI3K signaling through the 
dephosphorylation of PIP3 to PIP2. Regulation of PTEN itself is poorly 
understood; therefore, we sought to identify new PTEN interacting proteins 
by GST-pull down. P-Rex2a was one of the PTEN associated proteins 
identified. P-Rex2a is a guanine-nucleotide exchange factor for Rac and a 
member of the Rho-GTPase family of proteins. We have shown that P-
Rex2a inhibits PTEN phosphatase activity. Furthermore, P-Rex2a 
expression leads to increased PI3K signaling by upregulating 
phosphorylated Akt. Expression of P-Rex2a in the non-transformed human 
mammary epithelial cell line MCF10A causes increased growth under 
starvation conditions. In addition, P-Rex2a cooperates with mutations in 
PIK3CA to transform MCF10As and also with NeuT to form tumor 
xenografts in nude mice. Furthermore, the physical PTEN/P-Rex2a 
interaction is being mapped and the mechanism of PTEN inhibition is being 
analyzed. 
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PTEN PLAYS A PIVOTAL ROLE IN RETINAL NEUROGENESIS BY 
SUPPORTING NOTCH SIGNALING 
 
Hong seok Jo1, Kyung Hwa Kang1, Jaeho Lee1, Cheol O. Joe1, Greg 
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Neurogenic programs guiding the development of a given repertoire of 
neurons that arise from neural progenitor cells (NPCs) are closely linked to 
the general cellular phenomena of cell growth, proliferation, and survival. 
Multiple developmental cues that affect neurogenesis act simultaneously on 
NPCs, thus intracellular signaling hubs that integrate various external 
signals and influence general cellular events are required to balance the 
maintenance of NPCs with their differentiation into neurons. Here, we 
propose that phosphatase tensin homolog (PTEN) is located at the 
intracellular signaling hub in retinal progenitor cells (RPCs) and controls 
the speed of retinal neurogenesis. Mouse RPCs lacking the Pten gene 
completed neurogenesis earlier than regularly scheduled, resulting in 
precocious depletion of the RPC population. We found that hyperactivated 
Akt in Pten-deficient RPCs inhibited the formation of Notch transcription 
activator complex through phosphorylation of the Notch intracellular 
domain, and consequently interfered with Notch-supported RPC 
maintenance. We further demonstrated a coordinated oscillation of Akt 
activation and phosphorylation-dependent inactivation of Notch during cell 
cycle progression. Taken together, our results indicate that PTEN plays a 
pivotal role in retinal neurogenesis by controlling the negative feedback 
loop of phosphoinositide 3-kinase (PI3K)-Akt signaling to Notch. 
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PTEN (Phosphatase and tensin homolog deleted on chromosome 10) is a 
lipid phosphatase that mainly antagonises the PI3K signalling pathway by 
transforming the phosphatidyinositol 3 phosphate lipid (PIP3) into 
phosphatidyinositol 2 phosphate (PIP2). As a tumour suppressor, PTEN has 
been largely studied for its role in cancer, however little is known about its 
function and regulation in the central nervous system.  
We have recently identified novel proteins that form complexes with PTEN 
in brain tissue by mass spectrometry. One brain specific interactor was 
characterised as drebrin: 5 peptides matched the drebrin entry (Q07266) 
with a total coverage of 15% and initial characterisation verified the 
PTEN/drebrin interaction by co-immunoprecipitation from rat brain lysate. 
Drebrin is an actin binding protein that is largely known for its function in 
the formation of filopodia. In particular, drebrin governs spine 
morphogenesis and overexpression of drebrin in hippocampal neurons 
induces a drastic increase in the length of the dendritic filopodia. In order to 
test whether PTEN directly interacts with drebrin we analysed the FRET 
efficiency between PTEN-GFP and drebrin-mCherry by multiphoton FLIM 
in PC12 cells. This approach showed reproducible hot spots in the reduction 
in lifetime that indicate sites of direct PTEN/drebrin interactions. 
Interestingly, these sites of interaction were specifically localized in the 
periphery of cells that showed highly differentiated morphologies, and 
never in cells with non-differentiated, flat morphologies. Similarly, direct 
PTEN/Drebrin interactions were observed in filopodial protrusions in 
primary hippocampal neurons.  
In summary, we have identified the interaction of two proteins that have 
individually been linked to controlling dendritic spine morphology. We 
hypothesize that the association of PTEN with the actin binding protein 
drebrin governs essential processes during re-organisation of the actin 
cytoskeleton at the synapse and here we will present our data that test the 
relevance of this interaction in the formation and maintenance of dendritic 
spines in hippocampal neurons. 
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AGC Kinases AKT and PKBR1 play a crucial role in chemotaxis and 
multicellular development in Dictyostelium. They are both phosphorylated 
at PDK1 sites by PDK1 kinase and at PDK2/HM sites by TORC2. 
However, they have different localizing domains. AKT has a PI(3,4,5)P3-
regulated PH domain while PKBR1 is myristoylated and persistently 
located on the membrane independently of PI(3,4,5)P3. Using strains 
defective for PI(3,4,5)P3-, PDK1-, and TORC2-signaling or that express 
phospho-site mutants of AKT and PKBR1, we demonstrate that PDK2/HM 
site phosphorylation is insufficient for kinase activation; the activations 
absolutely require PDK1 site phosphorylation. However, both PDK1 site 
phosphorylations are dependent on PDK2/HM site phosphorylations. We 
also show that Dictyostelium PDK1 is persistently localized on the 
membrane via a PH domain but independently of PI(3,4,5)P3. Finally, we 
show that AKT and PKBR1 exhibit substrate selectivity and identify 2 
novel lipid-interacting proteins preferentially phosphorylated by AKT. 
Despite certain similarities, AKT and PKBR1 have distinct regulatory paths 
that impact activation and effector targeting. These findings from an ancient 
multicellular organism prove the conservative property of this important 
pathway, and the PI(3,4,5)P3 independent PKBR1 and PDK1 functions 
provide a unique chance to re-examine the current knowledge in 
mammalian systems. 
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RUNX3 is a prominent tumor suppressor in human cancers. This is 
highlighted by the frequent inactivation of RUNX3 due to promoter 
hypermethylation or protein mislocalisation in the gastrointestinal tract (GI) 
epithelium. As a transcription factor, RUNX3 is known to suppress cell 
growth by inducing the cell cycle inhibitor p21/CIP1 as well as the 
proapoptotic gene Bim in gastric epithelial cells. We have reported that 
TGF-/BMP and Wnt signaling pathways regulate RUNX3. To further 
elucidate the cellular regulation and functions of RUNX3 in the GI tract, we 
undertook a proteomics approach to identify new interacting partners of 
RUNX3. We re-introduced RUNX3 by an inducible system into DLD1 
cells, a RUNX3-deficient human colorectal cancer line. From the purified 
RUNX3 protein complexes, we identified protein kinase AKT as a novel 
RUNX3-binding partner. Binding was validated by in vitro binding assays 
as well as endogenous co-immunoprecipitation. Using bioinformatics and 
an AKT-substrate-specific antibody, we identified a residue within the 
conserved Runt domain that interacts with its transcription co-factor CBFβ 
and is phosphorylated by AKT. We will present new evidence on the role of 
PI3K/AKT in the regulation of RUNX3 in colorectal carcinogenesis. 
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In the search for new targets, the PI3K signaling pathway has emerged as a high 
potential target. The PI3K pathway is mutationally activated in a higher 
frequency of tumors and in more molecules in the pathway in breast cancer than 
any other pathway with at least one-half of human breast cancers harboring 
oncogenic aberrations. Mutation of PIK3CA, the gene encoding the p110a 
subunit of PI3K, is the most frequently occurring somatic aberration in breast 
cancer being present in approximately 25% of breast cancer, with most common 
amino acid mutations found at positions E545K, H1047R, and H1047L. 
Strikingly, mutation of PI3K, loss of PTEN, amplification of PIK3CA, AKT, 
PDK1, KRAS and p70S6K as well as increased signaling through cell surface 
receptors such as HER2 and EGFR result in activation of the PI3K pathway in 
more than 70% of breast cancers. In addition, upregulation of signaling through 
the PI3K pathway has been linked to poor prognosis and therapy resistance 
across the different types of breast cancer.  
In the present work we developed a model of breast human epithelial cell line 
harboring PIK3CA mutations and chose two of the most frequent mutations at 
positions E545K and H11047R to overexpress in MCF10A cells. 
Overexpression of the mutants resulted in increased invasion through matrigel 
and induced epithelial-mesenchymal transition in MCF10A cells. This 
observation was followed by a decrease expression of epithelial markers such as 
E-cadherin and an increase expression of mesenchymal markers such as N-
cadherin and Vimentin. Consistent with the invasiveness phenotype, we also 
observed an increase of MMP2 activity and higher levels of invasion markers, 
including FAK, PAK and Paxilin. In addition, the expression of EGFR and 
HER2 was also increased in E545K and H1047R expressing cells. 
Despite the observation that the expression of both EGFR and HER2 were 
elevated, the treatment of E545K and H1047R expressing cells with Lapatinib, 
a receptor tyrosine kinase inhibitor, showed an increased AKT phosphorylation 
and a sustained HER2 activation when compared to parental and DMSO treated 
MCF10A cells. Our results suggest that the presence of oncogenic mutation of 
PIK3CA caused a rapid resistance response to Lapatinib treatment and a bypass 
mechanism through AKT activation. 
Our results indicate that the presence of PIK3CA mutations not only increased 
cell invasiveness but also induced drug resistance in epithelial breast cells. 
Therefore the analysis of the mechanism behind the oncogenic effects of 
PIK3CA will to lead to a more effective treatment choice for breast cancer 
patients bearing mutations on PI3K. 
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In our lab we have identified CD95 as a factor contributing to non-apoptotic 
signals in neural cells. We investigated the role of CD95 signalling in 
glioma cells and used CD95-induced apoptosis-susceptible (LN18) and -
resistant (T98G) cell lines as a model system. In T98G cells CD95 
stimulation increases invasion. This response is mediated via novel 
CD95/Src/PI3K signalling pathway. mTOR (mammalian target of 
rapamycin) is a know downstream target of PI3K. It was originally 
described as a cell growth regulator but it has also been associated with the 
inhibition of apoptosis. Accordingly, we observed increased 
phosphorylation of S6 kinase and S6 ribosomal protein, both mTOR 
downstream targets, in T98G but not in LN18 upon CD95 stimulation. 
However, inhibition of mTOR by rapamycin does not increase CD95-
induced cell death of T98G. We have also analyzed the transcripts 
differentially regulated in T98G upon CD95 stimulation both at the total 
and polysome-bound RNA level. Gene Ontology analysis reveals down-
regulation of genes associated with cell adhesion and cell cycle and up-
regulation of those responsible for cell motility and metabolism of 
biopolymers, which correlates with the invasive phenotype induced by 
CD95L in those cells. Our aim is to fully characterize the differences 
between both cell lines at the molecular level, information that might be 
used to modulate the CD95 output signal. 
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PTEN is a tumor suppressor frequently mutated in human cancers. The 
PTEN protein is a lipid phosphatase that mediates many of its effects on 
growth, proliferation and survival through its PtdIns(3,4,5)P3 lipid 
phosphatase activity by suppressing the PI3-Kinase signalling pathway. 
PTEN also has protein phosphatase activity in-vitro and there is evidence 
that some of the processes regulated by PTEN could be attributed to its 
protein phosphatase activity such as inhibiting cell migration and invasion. 
To analyze PTEN’s protein phosphatase activity, our group has previously 
systematically developed a PTEN mutant PTEN Y138L, which has lipid 
phosphatase activity very similar to wild type PTEN but lacks detectable 
protein phosphatase activity. Experiments with this mutant provide 
evidence for the interfacial activation of PTEN against lipid substrates. 
They also indicate that when re-expressed in PTEN null glioblastoma cells 
at a physiological level and these cells are grown in Matrigel, both the lipid 
and protein phosphatase activities of PTEN independently contribute 
towards inhibition of cellular proliferation. However both activities are 
required together to achieve efficient inhibition of invasion (Davidson et al., 
2009).  
The only tumour mutant reported in the literature at Tyrosine 138 is a 
Cysteine mutation in a small cell lung carcinoma. From preliminary 
experiments it seems that this mutant, PTEN Y138C, like PTEN Y138L, 
retains activity against PIP3 but not against PolyGluTyr-P and in cultured 
cells it controls Akt activation as effectively as wild type PTEN. These data 
support the importance of the protein phosphatase activity of PTEN in 
tumour suppression as this appears to have been selectively lost in this lung 
tumor.  
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Aneuploidy, an abnormal number of chromosomes, is a hallmark of most 
human cancers and can drive neoplastic growth. One mechanism through 
which whole chromosome instability (W-CIN) can promote tumorigenesis 
is by accelerating loss of tumor suppressor genes. While studying the role of 
chromosome reshuffling in Pten loss of heterozygosity, we noticed that 
inactivation of a single Pten allele is sufficient to cause aneuploidy, 
suggesting a role for Pten in the chromosome segregation process. Live cell 
imaging revealed that Pten haploinsufficient mouse embryonic fibroblasts 
(MEFs) are indeed prone to multiple kinds of chromosome segregation 
errors, including congression failure, chromosome lagging and chromatin 
bridging. Importantly, these mitotic phenotypes were not accompanied by 
overt structural chromosome changes, such as chromosome breaks and 
chromosome-to-chromosome fusions. Next, we exploited a conditional 
knockout approach to examine whether complete loss of Pten would 
aggravate the mitotic defects associated with Pten haploinsufficiency. Pten 
null MEFs indeed showed substantial increases in congression failure, 
chromosome lagging and chromatin bridging, with 79% of cells showing at 
least one of these defects versus 59% of Pten haploinsufficient MEFs and 
15% of wild-type MEFs. Colcemid challenge assays revealed that Pten 
insufficient MEFs have compromised mitotic checkpoint activity. Taken 
together, these data identify Pten as a W-CIN gene required for proper 
microtubule-kinetochore attachment and mitotic checkpoint signaling. 
These findings raise the interesting possibility that inactivation of a single 
Pten allele accelerates the loss of the remaining wild-type allele, and 
suggest that prevention of whole chromosome instability represents a novel 
tumor suppressive function of Pten. 
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The PH domain Leucine-rich repeat Protein Phosphatase, PHLPP, plays a 
central role in controlling the amplitude of growth factor signaling by 
directly dephosphorylating and thereby inactivating Akt. Here we show that 
the cellular levels of the two splice variants, PHLPP1α and PHLPP1β, but 
not PHLPP2, are enhanced by their substrate, activated Akt, providing a 
negative feedback loop to tightly control cellular Akt output. Specifically, 
we show that the steady-state level of PHLPP1β, but not PHLPP2, is 
markedly reduced in cells in which Akt has been pharmacologically 
inhibited or in mTORC2-deficient cells, which lack fully-functional Akt. In 
these cells, introduction of a constitutively active Akt, but not kinase-
inactive Akt, stabilizes PHLPP1β. Consistent with Akt activity controlling 
PHLPP1β levels, a screen of the NCI 60 cell lines revealed a significant 
correlation between the levels of basal Akt activity and levels of PHLPP1β 
protein. Thus, the level of PHLPP1β in the cell is set by the amount of its 
substrate, phosphorylated, active Akt. Importantly, this correlation was lost 
in all four glioblastoma cell lines examined, but not in cell lines derived 
from less aggressive astrocytomas, suggesting loss of the feedback loop is 
an event that occurs in later stage disease. Consistent with this, levels of 
PHLPP1β were insensitive to inhibition of Akt activity in the four 
glioblastoma cell lines, but not in the astrocytoma cell lines. This negative 
feedback loop is preferentially lost in glioblastoma and may contribute to 
amplified Akt signaling in this cancer. 
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Genomic deletions of several hundred kb centering on the PTEN gene are 
frequent in prostate cancer (CaP), and have been shown to confer a poor clinical 
outcome. We have shown that hemizygous PTEN deletions in CaP are 
associated with earlier biochemical relapse, and that homozygous deletions of 
the gene are strongly linked to metastasis and androgen independent 
progression (Yoshimoto et al, 2007; Sircar, 2009; Squire, 2009). These, and 
other studies in both human and mouse models of CaP draw attention to the 
idea that pten protein dosage reduction is a major selective force of both onset 
and progression in CaP. In this study we have mapped the location of human 
CaP-specific PTEN deletions by a combination of microarray comparative 
genomic hybridization and FISH methods. Four-color FISH was performed 
using a cohort of 330 localized and hormone-refractory CaP tissue microarray 
on and 6 BAC clones spanning both PTEN genomic locus and several kb 
centromeric and telomeric to the gene. PTEN genomic deletions were observed 
in 132 (40%) CaP samples. FISH analyses showed that the most frequent 
genomic loss (including both hemi- and homozygous deletions) at 10q23 was a 
recurrent interstitial, restricted to several hundred kb in size that always 
included the PTEN gene. The second most frequent class of deletion was more 
heterogeneous and involved loss of PTEN and the neighboring FAS locus. 
Variations of deletion size suggest that 10q23 genomic region is highly unstable 
and is prone to CaP–specific DNA rearrangements. Within the most frequently 
deleted region there is a fragile site (FRA10A) that may be involved in a subset 
of deletion events. Furthermore, bioinformatics analysis identified at least three 
clusters of non-redundant regions of microhomology surrounding PTEN gene 
locus by paired intrachromosomal segmental duplications. We propose a model 
in which defects of homology-dependent DNA recombination and/or repair 
process in prostatic somatic cells, lead to a propensity for prostate cancer 
precursors to undergo genomic PTEN deletion. The high incidence of deletion 
in these cells may be facilitated by error-prone recombinational repair events 
that utilize the segmental duplication and copy-number variations sequences. 
Collectively these data highlight the role of sequence microhomology clusters 
surrounding the PTEN gene locus on genomic stability in CaP; and suggest that 
these regions may facilitate deletion events that lead to the decreased gene 
dosage of pten essential for CaP initiation and clinical progression. 
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Pluripotency of embryonic stem (ES) cells is defined by their capacity to 
generate all cell types in the body and is established by an interactive network 
of proteins namely Oct3/4, Nanog and Sox2 and their binding partners. 
Forkhead Box O (FoxO) of Forkhead family are evolutionary conserved 
transcription factors downstream of PI3-kinase/AKT signaling pathway whose 
function is inhibited by AKT phosphorylation. FoxOs are involved in the 
regulation of longevity, are essential for stress response and exert critical 
functions in adult stem cells and in many different tissues, however whether 
they are involved in the regulation of embryonic stem cells is not known. 
FoxO1, FoxO3, FoxO4 are wildly expressed while FoxO6 is specific to 
neuronal tissues. Whether FoxOs are redundant in their functions is not clear. 
Here we show that in undifferentiated self-renewing ES cells and during lineage 
specification FoxO protein expression is differentially regulated. In addition, 
using loss and gain of function approaches, we demonstrate that FoxO1, but not 
other FoxOs, is critical for maintenance of human ES (hES) cell pluripotency. 
Doxycycline Tet-On inducible shRNA knockdown of FoxO1 delivered by 
lentiviruses resulted in 90% reduction in expression of FoxO1 protein within 48 
hours associated with rapid and significant reduction in expression of Oct4, 
Sox2 and Nanog pluripotency proteins as measured by QRT-PCR and Western 
blot, reduction in expression of cell surface markers of pluripotency TRA-1 81 
and TRA-1 60 and SSEA4 as shown by immunofluorescent staining and flow 
cytometry, and inhibition of teratoma formation in mice. Consistent with this, 
knock down of FoxO1 led to the erroneous induction of mesoderm and 
endoderm differentiation under undifferentiation self-renewal conditions of hES 
cells. Four different cell lines generated by two distinct shRNAs targeting 
FoxO1 produced comparable results in hES cells. The striking impact of FoxO1 
knock down on hES cell pluripotency was not due to the loss of a generic 
function of FoxO1 on cell proliferation, survival or oxidative stress conditions. 
In addition, ectopic expression of FoxO1 but not FoxO3 (FoxO4 and FoxO6 are 
not expressed in undifferentiated hES cells) delivered by lentiviruses induced 
significant upregulation of Oct4 and Sox2 expression in both H1 and in HES2 
hES cells. We show that FoxO1 but not FoxO3 regulates the expression of Oct4 
and Sox2 by direct binding to, and activation of, Oct4 and Sox2 promoters. 
These results support a non-redundant function for FoxO1 in the regulation of 
hES cell fate. In addition, these findings have important implications for stem 
cells, development and reprogramming. 
 28 
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At least in vitro, the tumor suppressor phosphatase PTEN displays intrinsic 
activity towards both protein and phosphatidylinositol phospholipid 
substrates. Whereas the lipid phosphatase activity of PTEN is important for 
its tumor suppressor function, the significance of its protein phosphatase 
activity is unknown and represents a gap in our understanding of the 
function of this important regulator of cell signaling. We have developed an 
in vivo assay of PTEN function, which has revealed an effect of its protein 
phosphatase activity on the density of neuronal spines in cultured 
hippocampal organotypic brain slices. The approach utilized two-photon 
laser scanning microscopy and biolistic gene delivery of GFP-tagged 
constructs into organotypic slices of the hippocampus. The organotypic 
slice culture system maintains the tissue architecture of the hippocampus 
and produces a mosiac that permits analysis of the transfected neuron in a 
more natural context. We have observed that expression of wild type PTEN 
in organotypic brain slices led to a decrease in spine density. Strikingly, the 
lipid phosphatase-deficient, tumor-derived PTEN G129E mutant produced 
the same reduction in spine density as the wild type protein, whereas 
catalytically-dead (C124S) and protein phosphatase-deficient (Y138L) 
mutants were without effect. We tested expression of the isolated C2 
domain in our system, but observed no effect on spine density. We also 
focused on the four C-terminal phosphorylation sites of PTEN and prepared 
mutants in which they were changed to non-phosphorylatable Ala residues 
(4A mutants). Introduction of the 4A mutation into wild type PTEN did not 
affect its ability to induce a decrease in spine density. More interestingly, 
combining the C124S and 4A mutations now also led to a decrease in spine 
density, unlike the inactivating C124S mutation alone. These data suggest 
that there may be a difference in the phosphorylation status of this cluster of 
sites in WT and C124S mutant PTEN. We used mass spectrometry to 
determine the phosphorylation status of this segment of PTEN in protein 
ectopically expressed in 293 cells. In contrast to wild type and G129E 
mutants, which are both active as protein phosphatase, we detected 
phosphate on these sites in the inactive C124S PTEN mutant. Interestingly, 
PTEN was shown initially to favor acidic substrates and these sites are 
located in an acidic stretch of the protein. Our data suggest that the protein 
phosphatase activity of PTEN and the phosphorylation of these C-terminal 
residues are of regulatory significance to the control of spine density. The 
critical protein substrate for PTEN may be PTEN itself. 
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Mechanisms of sensing chemotactic gradients are remarkably similar in 
Dictyostelium amoebae and mammalian leukocytes. The upstream 
components and reactions in the signaling pathway are uniformly 
distributed along the membrane while downstream responses such as PIP3 
accumulation and actin polymerization are sharply localized towards the 
high side of the gradient. Gradients of chemoattractant cause PI3Ks and 
PTEN to bind to the membrane at the front and the back of the cell, 
respectively, leading sharp accumulation of PIP3 at the anterior. A similar 
PIP3-based "polarity circuit" plays a key role in cytokinesis where PI3Ks 
and PTEN move to and function at the poles and furrow, respectively, of the 
dividing cell. Disruption of PTEN broadens PIP3 localization and actin 
polymerization in parallel, interfering with chemotaxis and cytokinesis.  
 
Although human PTEN (hPTEN) can rescue the deficiencies of pten¯ cells, 
only very low levels of hPTEN are associated with the membrane. 
Membrane binding is limited by all phosphorylation-dependent 
intramolecular interaction that maintains hPTEN in a “closed” 
conformation. The phosphorylated “tail” portion of hPTEN binds tightly to 
the rest of the protein. Removal of the tail or inhibition of phosphorylation 
leads to strong membrane association.  
 
We have recently shown that activations of TorC2 and PKBs occur at the 
leading edge of chemotaxing cells and play a critical role in directed cell 
migration. Activation of PKBA requires PIP3 while activation of PKBR1, a 
myristoylated form, persistently bound to the membrane, is independent of 
PIP3, and depends only on TorC2. Using the latter system, we are able to 
show that RasC activates TorC2 to phosphorylate the hydrophobic motif of 
PKBR1. The abberent motility caused by expression of constitutively active 
RasC is suppressed by disruption of the signature TorC2 subunit, PiaA.  
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Britta J Eickholt1, Tomas Perez1, Michiel T van Diepen1, Maddy Parsons2, 
Nick Leslie3  
1King's College London, MRC Centre for Developmental Neurobiology, 
New Hunt's House, London, SE1 1UL, United Kingdom, 2King's College 
London, The Randall Division of Cell and Molecular Biophysics, New 
Hunt's House, London, SE1 1UL, United Kingdom, 3University of Dundee, 
Division of Molecular Physiology, College of Life Sciences, Dundee, DD1 
5EH, United Kingdom 
 
We recently demonstrated a requirement for functional actin-based motor 
proteins in the control of PI3K signalling, a mechanism involving a 
previously unknown association between PTEN and class V Myosins (van 
Diepen et al., 2009, Nat Cell Biol 11, 1191-6). FRET measurements 
revealed that PTEN interacts directly with MyosinV at discreet cellular sites 
dependent on PTEN phosphorylation. In addition, inactivation of MyosinV-
transport function in CNS neurons affects neuronal soma size in vitro and in 
vivo, which – in line with known attributes of PTEN-loss - required PI3K 
and mTor.  
Here we will present our current work testing the functional significance of 
the PTEN:MyosinV interaction in regulating PI3K signalling and neuronal 
morphogenesis in response to growth factors and axon guidance cues.  
 
Grant support: Wellcome Trust - Ref 083449  
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THE REGULATION AND MECHANISMS OF ACTION OF THE PTEN 
ENZYME 
 
Nick R Leslie  
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PTEN is a lipid phosphatase that acts as a component of the core 
phosphoinositide 3-kinase (PI3K) signal transduction pathway. Most 
tumours display increased activity of components of the PTEN/PI3K 
signalling pathway. In particular loss of function mutations of PTEN are 
amongst the most frequent genetic changes in human cancers. Also, several 
novel candidate tumour suppressors and oncogenes have been identified 
recently which appear to affect tumour development principally via effects 
on PTEN. 
 
As part of work to understand how loss of PTEN function and regulation 
contribute to tumour development, we are investigating PTEN’s ability to 
dephosphorylate both phosphoinositide lipids and peptide substrates. We 
have approached this through the development of mutants that selectively 
metabolise either lipid or protein substrates. These mutants were tested in 
cell based assays of PTEN function using viral re-expression of PTEN at 
physiological levels in U87MG glioblastoma cells that lack the 
phosphatase. The data indicate that PTEN’s protein phosphatase activity is 
not required for its control of total cellular levels of its substrate, PIP3, or 
signaling via the PIP3-regulated protein kinase, Akt. PTEN’s lipid 
phosphatase activity seems to dominate in the regulation of cellular 
proliferation. However, both lipid and protein phosphatase activities appear 
to act together to inhibit invasion in 3D matrigel culture. I will present data 
from this project addressing the relative significance of PTEN’s lipid and 
protein phosphatase activities and also from studies of the regulation of 
PTEN by ubiquitination.  
 32 
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PTEN is an essential tumor suppressor gene and it has a crucial role in 
embryonic development. The zebrafish is an ideal model to study vertebrate 
development and we have used it to further investigate the function of Pten 
in embryonic development. In the zebrafish genome two pten genes, ptena 
and ptenb were identified, which were shown to have redundant functions 
during embryogenesis. Whereas ptena-/- or ptenb-/- mutants did not show 
embryonic phenotypes, double mutant embryos died at 5 days post 
fertilization. An increased level of p-Akt in pten double mutant embryos 
indicated that the PI3K/Akt pathway was dysregulated in embryos lacking 
functional Pten. Injecting double mutant embryos at the 1-cell stage with 
pten RNA partially rescued the double mutant phenotype and significantly 
reduced the p-Akt level in these embryos. Live imaging of developing 
zebrafish embryos using fluorescently labeled Pten fusion proteins revealed 
a specific, highly dynamic behavior of the Pten protein. Pten was restricted 
from the nucleus, but a rapid nuclear influx was observed immediately prior 
to cell division. Currently, we are analyzing this behavior of Pten, using a 
panel of Pten mutants. The role of transient nuclear localization of Pten in 
normal physiological functions and in embryonic development will be 
discussed. 
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PTEN (Phosphatase and Tensin Homolog on Chromosome 10) was 
discovered as a candidate tumor suppressor in 1997. Since that time, much 
effort by many laboratories has established that PTEN:  
 
1) is altered by mutation or indirect mechanisms in various types of cancer  
 
2) antagonizes PI3K signaling via its lipid phosphatase activity  
 
3) regulates signals that are independent of the PI3K pathway  
 
4) suppresses spontaneous cancer development in mice in many differrent 
organ systems  
 
5) modulates sensitivity to cancer therapy  
 
6) controls cellular proliferation, size, survival, metabolism, sensecence, 
migration and stemness  
 
7) resides in different cell compartments (plasma membrane, cytoplasm, 
nucleus)  
 
8) is regulated by mutiple mechanisms  
 
9) contributes to normal development of different organ systems and has 
been implicated in non-cancer diseases of the neurological, reproductive, 
endocrine and inflammatory systems.  
 
Past progress and recent advances will be presented. 
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The use of mice as genetic tools to study the molecular basis of brain 
development and function has grown steadily over recent years. Recent 
human genetic studies have implicated the PI3 Kinase pathway as an 
underlying cause of a small subset of autism cases that are related to 
genetically inherited diseases. Using mutant mouse models, we have shown 
that modulation of the PI3 Kinase pathway can be an indirect source of 
synaptic modulation. Moreover, mice lacking PI3 Kinase components in 
mature neurons exhibit stereotypic behavioral abnormalities reminiscent of 
autism. Because this signaling pathway is also implicated in many human 
cancers, drugs that inhibit this pathway are in development. We have 
applied such drugs, including the specific mTORC1 inhibitor rapamycin in 
Pten mutant mice, with promising outcomes. It is our hope that continued 
study of these mice will provide insights into the anatomical and cellular 
basis of at least a subset of autism spectrum disorders. 
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PATHWAYS, HUMAN DISEASE, AND MOUSE MODELS 
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Tuberous Sclerosis Complex (TSC) is an autosomal dominant disorder due 
to inactivating mutations in either TSC1 or TSC2, and characterized by 
development of benign yet proliferative tumors in multiple organs. Cortical 
tubers associated with a variety of neurological syndromes, and tumor 
involvement of the kidney (angiomyolipomas) and lung 
(lymphangioleiomyomatosis) are the greatest clinical problems in this 
disorder. 
In this presentation, I will review human therapeutic trials in this disorder 
using rapamycin, and recent results on a related neoplasm, PEComa. I will 
describe the development of a hypomorphic allele of Tsc2 in mice. I will 
present results on the contribution of Tsc1 loss to lung cancer development 
in a mutant Kras driven mouse model, and the lack of involvement of TSC1 
or TSC2 in human lung cancer. I will discuss recent studies that clarify the 
role of TSC1 in the development of human bladder cancer. I will present 
recent results on the development of novel models of TSC brain disease, 
and the benefit of prenatal treatment of one such model with rapamycin. 
Finally, I will present results on deep sequencing of cortical tubers for 
second hit events in TSC1, TSC2, and KRAS. 
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The mammalian Target Of Rapamycin (mTOR) signal transduction is a 
master regulator of cell size, number and metabolism and is activated in the 
majority of human cancers. S6K and Akt protein kinases are activated by 
two distinct branches of mTOR signaling cascade – mTORC1 and 
mTORC2 respectively. 
Inhibition of mTOR kinase has proven efficacy in PTEN-negative mouse 
models of cancer, though the mTOR complexes (mTORC) and substrates 
involved in tumorigenesis are under investigation. Despite the recent 
progress in understanding the components and interplay between them the 
question how mTOR signaling controls tumorigenesis is still open. 
Using mouse model of liver cancer triggered by PTEN deletion we revealed 
that development of steatohepatitis-associated liver adenocarcinomas 
specifically requires Akt2, while the Akt1 homologue and S6K1 and S6K2 
are dispensable. In this model rapamycin analogues partially inhibit Akt 
phosphorylation and decrease tumour growth. Akt2 deletion affects a 
number of metabolic parameters in PTEN-deficient livers, including the 
hypoglycaemic action of insulin, the PPAR g-dependent program leading to 
lipid accumulation and the expression of specific glycolytic isozymes such 
as hexokinase II and M2 pyruvate kinase (PKM2). Akt2 is involved in 
regulation of PKM2 and HXKII on mRNA and protein level as well as 
promotes association of HXKII with mitochondria. PTEN negative human 
hepatocellular carcinoma cell lines also display PKM2 upregulation in an 
Akt2-dependent manner, providing an advantage for cell proliferation and 
anchorage independent growth. Our data have implications on the link 
between the metabolic action of insulin signal transduction and 
tumorigenesis, identifying Akt2 as a potential therapeutical target in liver 
malignancies depending on cancer genotype.  
The recent developments on the project will be presented. 
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Approximately 90% of malignant tumors arising in the urinary bladder 
are of epithelial origin, the majority being transitional cell carcinomas. Early 
stage bladder tumors have been classified into two groups with distinct behavior 
and unique molecular profiles: low grade tumors (always papillary and usually 
superficial), and high-grade tumors (either papillary or non-papillary, and often 
invasive). Clinically, superficial bladder tumors (stages Ta, Tis, and T1) 
account for 75% to 85% of neoplasms, while the remaining 15% to 25% are 
invasive (T2, T3, T4) or metastatic lesions at the time of initial presentation. 
Metastatic bladder cancer is an important focus of research because, in most 
cases, cancer-related death is the result of systemic disease rather than the 
primary tumor. Even with recent improvements in primary therapy and systemic 
chemotherapy, the median survival for patients with unresectable metastatic 
bladder cancer is approximately 7-20 months. Since criteria to determine 
treatment in a particular patient are incompletely defined, new biological 
determinants are needed for proper selection and monitoring of therapy.  
        Studies from our group and others have revealed that distinct genotypic 
and phenotypic patterns are associated with early versus late stages of bladder 
cancer. Most importantly, early superficial diseases appear to segregate into two 
main pathways. Briefly, chromosome 9 deletions and mutations of RAS and 
FGFR3 are observed in most if not all superficial papillary non-invasive tumors 
(Ta), but only in a small subset of invasive bladder neoplasms. However, 
deletions of 3p, 5q, 10q (PTEN locus), 11p, 13q (RB locus), 17p (TP53 locus), 
and 18q (DCC locus) are absent or very rare in the Ta tumors analyzed, but 
have been frequently identified in invasive bladder carcinomas. Based on these 
data, a novel model for bladder tumor progression has been proposed in which 
two separate genetic pathways characterize the evolution of superficial bladder 
neoplasms. Transgenic models using tissue specific promoters, such as that of 
uroplakin II, are being utilized to generate genetic proof of the relevance of 
certain genes in the context of bladder cancer. Working with the group of Dr. 
Abate-Shen, we established an alternative procedure to achieve gene 
recombination specifically in bladder epithelium by delivery of an adenovirus 
expressing Cre recombinase into the bladder lumen. Using this approach, we 
have shown that combinatorial deletion of Pten and p53 tumor suppressor genes 
in bladder epithelium results in invasive bladder tumors that resemble their 
human counterpart. Additionally, we have developed a renal graft model of 
human bladder cancer and have shown that combinatorial inactivation of Pten 
and p53 promotes bladder tumorigenesis in this human model of bladder cancer. 
Furthermore, we have found that deregulated expression of Pten and p53 is 
associated with poor survival in clinical specimens of invasive bladder cancer in 
humans. Finally, we have shown that the mechanisms by which inactivation of 
Pten and p53 promote bladder tumorigenesis are mediated, in part, by activation 
of mTOR signaling and that inhibition of this signaling pathway with 
Rapamycin inhibits bladder tumors in a preclinical mouse model. These and 
other models, along with translational studies, will be presented. 
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Like normal stem cells, cancer stem cells (CSC) have the capacity for 
indefinite proliferation and generation of new cancerous tissues through 
self-renewal and differentiation. Among the major intracellular signaling 
pathways, Wnt, Shh, and Notch are known to be important in regulating 
normal stem cell activities and their alterations are associated with 
tumorigenesis. It has become clear recently that phosphatase and tensin 
homologue (PTEN) is also critical for stem cell maintenance and that PTEN 
loss can cause the development of CSCs and ultimately tumorigenesis. I 
will discuss our recent findings on suppression of PTEN null CSCs 
transformation and cancer development. 
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We recently demonstrated the ability of lovastatin, an inhibitor of 
mevalonate synthesis, to inhibit the function of the epidermal growth factor 
receptor (EGFR) and its downstream signaling of the PI3K/AKT pathway. 
Combining lovastatin with gefitinib, a potent EGFR inhibitor, induced 
synergistic cytotoxicity in various tumour derived cell lines. In this study, 
lovastatin treatment inhibits ligand-induced EGFR dimerization in 
squamous cell carcinoma (SCC) cells and its activation of AKT and its 
downstream targets 4EBP1 and S6K1. This inhibition was associated with 
global protein translational inhibition demonstrated by a decrease in RNA 
associated polysome fractions. The effects of lovastatin on EGFR function 
were reversed by the addition of the mevalonate metabolite geranylgeranyl 
pyrophosphate that acts as a protein membrane anchor. Lovastatin treatment 
induced actin cytoskeletal disorganization and the expression of the 
geranylgeranylated rho family proteins in SCC cells that regulate the actin 
cytoskeleton, including rhoA. Lovastatin-induced rhoA was inactive as 
EGF stimulation failed to activate rhoA and inhibition of the rho-associated 
kinase, a target and mediator of rhoA function, with Y-27632 also showed 
inhibitory effects on EGFR dimerization. The ability of lovastatin to inhibit 
EGFR dimerization by targeting rho function is a novel exploitable 
mechanism regulating this therapeutically relevant target. 
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Malformations of cortical development (MCDs) are disproportionately 
represented in cases of pharmacologically refractory seizures, yet the 
underlying cellular contributions to epileptogenesis are incompletely 
understood. MCDs compose a wide variety of neurological disorders with a 
proportionately diverse histopathology ranging from loss of cortical 
lamination to subcortical (band) heterotopias to dysplasias with cytomegalic 
cells. However, elevated mTOR signaling is a common feature of MCDs 
suggesting that the molecular determinants which lead to epileptogenesis 
may be conserved. Tuberous sclerosis complex (TSC) is a representative 
MCD for which inactivating mutations in one of two genes, Tsc1 or Tsc2, 
have been identified. Importantly, the protein products of Tsc1 and Tsc2 
negatively regulate mTOR signaling which is consequently elevated in TSC 
associated neurological lesions. Here we describe a novel mouse model of 
TSC for which biallelic inactivation of Tsc1 in radial glia by in utero 
electroporation generates neurological features of TSC. Tsc1 inactivation 
produces clusters of enlarged ectopic neurons with elevated mTOR 
signaling as indicated by increased phospho-S6 staining, nodules located 
either within the corpus callosum or protruding into lateral ventricles and a 
reduced latency for PTZ induced seizures. Preliminary experiments suggest 
that in utero electroporation of constitutively active mTOR phenocopies 
removal of Tsc1, however future experiments will be needed to address to 
what extent these features are reproduced. 
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Glioblastoma multiforme (GBM), the most common intracranial tumour in 
adults, exhibits a highly lethal and progressive clinical course despite 
intensive therapeutic intervention. Mutational activation of the Epidermal 
Growth Factor Receptor (EGFR) is common in GBM and concomitant loss 
of the PTEN tumor suppressor confers poor clinical response to the EGFR 
kinase inhibitors, erlotinib or gefitinib. Notably, however, activated EGFR 
tumors with intact PTEN show only modest treatment responses, pointing to 
additional resistance mechanisms. We considered the possibility that the 
marginal clinical responses of EGFR mutant (EGFRvIII) PTEN wild-type 
GBM cases might relate to functional inactivation of PTEN brought about 
by post-translational modifications. Using mass spectrometry, we have 
mapped Src-induced phosphorylation sites on PTEN. Using this 
information, we were able to raise phospho-specific antibodies against 
tyrosine 240 in the PTEN C2 domain. Application of these antibodies in 
immunohistochemistry has allowed us, for the first time, to directly 
demonstrate tyrosine phosphorylation of PTEN in human tumors. We 
observe that phosphorylation of PTEN at tyrosine 240 is associated with 
shorter survival in GBM patients and with resistance to EGFR inhibitor 
therapy. Using GBM cell lines, we show that blocking PTEN 
phosphorylation, either by phenylalanine substitution of a single tyrosine 
residue, Y240, or by the use of the tyrosine kinase inhibitor, dasatinib, can 
attenuate mutant EGFR signaling and enhance the cellular response to 
Erlotinib. Thus, in addition to co-activation of multiple RTKs and 
mutational inactivation of PTEN, Src-mediated functional inactivation of 
PTEN is a major modifier of an important class of cancer drug in human 
GBM. These findings inform the design of clinical studies combining Src 
and EGFR inhibition in PTEN-intact GBM and possibly in diverse solid 
tumor types driven by EGFR activation. 
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Pten a negative regulator of Phosphatidylinositol 3 kinase is expressed in 
osteoblasts. But the role of this tumor suppressor gene during bone 
development is not completely understood. To define a role for Pten during 
bone development we deleted Pten in mice by crossing Ptenflox/flox and 
the Dermo1cre deleter mice. Deletion of Pten in osteoprogenitor cells led to 
an expansion and formation of bone away from the growth plate in the 
perichondrium. In the Pten conditional knockout perichondrium we 
observed 1) increase in FGF18, a potent osteoblast mitogen 2) decrease in 
expression of Sprouty2 a repressor of FGF signaling. Increase in 
perichondral bone formation observed in the Pten conditional knockout 
could be explained by repression of Forkhead transcriptional factors by 
downstream effectors of activated PI3K leading to increased FGF signaling. 
This implicated unrestricted MAPK signaling as the major mediator of 
osteoblast differentiation in the absence of Pten. To test if FGF signaling is 
required for the phenotype we deleted one allele of FGFR2 to attenuate 
MAPK signaling and saw a partial rescue of the Pten null bone phenotype. 
To identify the progenitor population in the perichondrium required for the 
increased bone phenotype, we utilized SP7cre to delete Pten in bone and 
compared the phenotype in the perichondrium with the Dermo1cre 
knockout. The SP7cre did not show a perichondral phenotype, so we 
utilized a number of stem cell markers including NG2 ,N-cadherin and Slug 
and identified a population of cells in the perichondrium of the 
Pten/Dermo1cre that were differentially expanded when compared to the 
Pten/SP7cre. This study identifies an osteoprogenitor population in the 
perichondrium that leads to increased bone formation in the absence of 
Pten. 
 43 
GENETIC AND PRECLINICAL INTERROGATION OF A 
GENETICALLY ENGINEERED MOUSE MODEL OF SMALL CELL 
LUNG CARCINOMA. 
 
Patricia Hamilton, Jason Long, Anthony Lima, Rafael Molina, Hani Bou-
Reslan, Tim Cao, Michelle Nannini, Richard Carano, Li Li, William 
Forrest, Suzana Couto, Leisa Johnson 
Genentech, Molecular Biology, 1 DNA Way, South San Francisco, CA, 
94080 
 
Lung cancer is the leading cause of cancer deaths in the United States, with 
small cell lung carcinoma (SCLC) representing approximately 15% of all 
cases. Some of the principle molecular alterations that have been associated 
with human SCLC include loss of the RB, TP53 and FHIT tumor suppressor 
genes as well as amplification or increased expression of the C-MYC and 
BCL2 proto-oncogenes. We have begun to characterize the molecular events 
associated with SCLC progression using a genetically engineered mouse 
model (GEMM) driven by simultaneous loss of the Rb and Tp53 tumor 
suppressor genes following intranasal delivery of an adenovirus expressing 
the Cre and FLPe recombinases. Array comparative genomic hybridization 
(aCGH) analysis revealed frequent & focal copy number changes in Pten, 
Mycn, Mycl, and Nfib. As in mice, human SCLC frequently undergoes 
genetic copy number changes in the PTEN/PI3K pathway. In contrast to 
mice, frequent amplifications in PIK3CA and C-MYC were observed. 
Moreover, there was no apparent correlation between these copy number 
changes in either mice or humans. Further examination of PTEN expression 
levels in human SCLC by immunohistochemistry revealed the 
heterogeneous nature of PTEN expression, with 95% demonstrating altered 
expression &/or localization. Interestingly, the expression pattern of 
pAKTSer473 demonstrated that approximately one third of human SCLC 
samples have nuclear pAKT (when they are positive), with no obvious 
correlation between nuclear pAKT expression and PTEN loss. Preclinical 
interrogation of the SCLC GEMM revealed significant, cytotoxic effects on 
primary lung tumor burden when the pan PI3K inhibitor GDC-0941 was 
combined with carboplatin and anti-VEGF. These effects were highly 
durable and resulted in a significant overall survival outcome. Importantly, 
this triple therapeutic combination resulted in a significant impact on both 
primary and metastatic disease to the regional lymph nodes and liver, with 
~40% of the mice demonstrating no gross disease at necropsy. Human 
SCLC has a high mitotic rate and patients generally respond well to 
frontline chemotherapy. However, it is the residual disease that typically 
mediates therapeutic relapse and patient mortality. Our data with GDC-
0941 in combination with anti-VEGF and chemotherapy has important 
implications towards improving both the extent and duration of frontline 
chemotherapeutic responses in human SCLC, ultimately extending the time 
to disease progression and overall survival. 
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NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical 
trials. We profiled this compound against a panel of breast tumor cell lines 
to identify potential patient populations who would benefit from such 
treatment. This approach found breast cancer lines with HER2 amplification 
and/or PIK3CA mutations to be sensitive towards NVP-BEZ235 treatment 
as the compound induced strong cell death in these lines. In contrast, breast 
lines with PTEN loss of function or K-RAS mutations only showed growth 
arrest. Cell death induction seen with NVP-BEZ235 could as well be 
observed with other PI3K inhibitors, thus linking cell death to the inhibition 
of PI3K. Analysis of death markers revealed that cell death induced by 
NVP-BEZ235 is accompanied by active PARP cleavage, which is 
indicative of an apoptotic process. This did not seem to be mediated by the 
intrinsic apoptosis pathway since we could not detect activation of 
mitochondrial caspases nor could cells be protected by overexpression of 
Bcl2, an anti-apoptotic component of the intrinsic pathway. Instead, we 
observed disappearance of the full-length form of the extrinsic caspase 2, 
suggesting NVP-BEZ235 induces apoptosis via the extrinsic pathway. This 
study suggests that breast cancer patients with HER2 amplification and/or 
PIK3CA mutations might respond best to NVP-BEZ235 treatment, whereas 
patients with PTEN loss of function or K-RAS mutations might benefit less. 
Overall, this study will provide guidance for patient stratification for 
forthcoming breast cancer phase II trials for NVP-BEZ235. 
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Pten and P53 tumor suppressors are among the most commonly inactivated 
genes in prostate cancer. While loss of P53 alone results in no obvious 
phenotype, Pten deletion in the mouse prostate epithelium results in the 
development of carcinoma in situ with eventual progression to 
adenocarcinoma. Combined loss of PTEN and P53 leads to significantly 
more rapid and extensive prostate tumor development ultimately resulting 
in death from urinary outflow obstruction. Pten deletion alone has been 
implicated in the expansion of a prostatic stem/progenitor cell population, 
while Pten and P53 have recently been shown to act concomitantly not 
independently in the regulation of neural and glioma stem/progenitor cell 
renewal and differentiation. We hypothesize that Pten and P53 play a 
crucial role in regulating self-renewal and differentiation ability, two 
defining hallmarks of stem/progenitor cells. In order to test our hypothesis, 
we employed clonogenic 2D colony and 3D sphere formation assays aimed 
at measuring the progenitor and differentiation activity of cells isolated 
from Pten-/-P53-/- adenocarcinomas. Colony and sphere formation activity 
was monitored over at least 4 generations of serial propagation in vitro. 
Protospheres generated from Pten-/-P53-/- single cell suspensions were 
approximately 3 times larger than wild type (wt) spheres and demonstrated 
significant heterogeneity in morphology, displaying less uniform cell 
shapes. Sphere forming units (SFU) in single cell suspensions from Pten-/-
P53-/- prostates showed a 50%-80% increase when compared to wt. Pten-/-
P53-/- SFU activity was maintained upon serial passage of single cell 
suspensions for 4 generations, while a reduction in SFU activity was 
observed over the same 4 generations in wt. Similar findings were obtained 
from analyzing the colony forming ability of cells taken from wt and Pten-/-
P53-/- spheres. Pten and P53 deletion significantly affects the 
differentiation profile of colonies and spheres generated from knockout as 
compared to wt cells. Interestingly, an increased number of luminal, transit-
amplifying and neuroendocrine cells with a relative reduction in the number 
of basal cells were observed in the Pten-/-P53-/- spheres and colonies 
compared to wt. In addition, Pten-/-P53-/- progenitor cells demonstrate 
sensitivity to drugs targeting the mTOR (Rapamycin), AKT (Triciribine) 
and androgen receptor (Nilutamide and Bicalutamide) pathways. In 
conclusion, our findings to date confirm the presence of an amplified 
stem/progenitor cell population in Pten-/-P53-/- prostates that generates 
morphologically abnormal protospheres displaying changes in the relative 
production of differentiated progeny. 
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Analyzing biologic signaling networks is greatly facilitated when 
mathematical modeling is integrated with experimental data. In this study, 
we measured insulin-like growth factor signaling through receptor tyrosine 
kinase in the MDA-MB231 breast cancer cell line using reverse phase 
protein arrays to quantify the dynamic crosstalk between the 
phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase 
(MAPK) pathways. We developed a computational procedure that 
integrated mass-action modeling with particle swarm optimization to 
analyze the data. The mass-action model was trained using transient 
experimental data measuring phosphorylated protein levels to infer the 
unknown model parameters. We then used the model to identify regulatory 
molecules that could restore user-defined signaling network outputs when 
targeted with combinations of drug inhibitors and small-interfering RNAs. 
We tested and validated the combined effect of the most influential targeted 
perturbations predicted by the model using immunoblotting and cell 
viability assays. Our results showed that using optimal drug combinations 
led to desired rewiring of the signaling pathways and decreased cell 
viability. The integrative approach described here is useful for generating 
experimental intervention strategies that can lead to the rational use of drug 
combinations and the discovery of novel pharmacologic targets. 
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PI3K pathway alterations are frequent in invasive breast cancer. Invasive 
lobular carcinoma of the breast (ILC) is characterized by loss of expression 
of E-cadherin, infiltrative growth and formation of metastases. The majority 
of ILCs express estrogen receptor. However, besides endocrine therapy, 
pharmacologic treatment options are limited. This illustrates the need to 
find more therapeutic opportunities. We have developed a mouse model for 
ILC with tissue-specific conditional knock-out of E-cadherin and P53. 
These mice develop mammary tumors with a latency of around 200 days 
which phenotypically resemble human ILC, including invasive growth and 
metastatic spread. High expression of phospho-S6 in mILC tumors, 
determined by immunohistochemistry, indicates activation of the PI3K 
pathway. The tumors have been transplanted orthotopically in recipient 
mice in preclinical intervention studies to investigate therapeutic effects of 
inhibitors of the PTEN pathway. Cell lines have been derived from these 
tumors and have been shown to maintain high phospho-S6 expression. 
Several cell lines have been transfected with luciferase and orthotopically 
transplanted for in vivo monitoring of tumor growth and spread by 
bioluminescence. In parallel, a mouse cohort with mammary tissue-specific 
E-cadherin and PTEN knockout has recently been bred, providing a new 
relevant ILC model for mechanistic and preclinical studies. 
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Crosstalk between the Wnt and mTOR signaling pathways occurs at 
multiple levels in the cell and likely contributes to the oncogenic effects of 
these pathways in human cancer. To gain more insight into the interplay 
between Wnt and mTOR signaling in salivary gland tumorigenesis, we 
developed a mouse model in which both pathways are constitutively 
activated by conditional inactivation of the Apc and Pten tumor suppressor 
genes. Loss of Apc and Pten results in the formation of salivary gland 
tumors similar to human acinic cell carcinoma with 100% penetrance and 
short latency. Our results suggest that activated Wnt signaling deregulates 
the salivary gland stem cell compartment but does not on its own cause 
tumor formation. However, activation of mTOR signaling in this setting 
leads to rapid tumor development. Although activation of both pathways is 
required for tumor initiation, aberrant mTOR activity appears to play a 
pivotal role in acinic cell tumorigenesis. Treatment of tumor-bearing mice 
using a low dose of rapamycin caused the tumors to completely regress. 
Consistent with these results, we found that acinic cell carcinomas of both 
the mouse and human salivary gland always express markers of activated 
mTOR signaling. Given the availability of rapamycin and its analogs for 
treatment of several other types of human malignancy, rapamycin may also 
be useful in treating human acinic cell carcinoma of the salivary gland. The 
current treatment options for metastatic disease are limited because most 
acinic cell carcinomas do not respond to chemotherapy.  
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Prostate cancer is the most common male cancer in Western societies. Few 
specific molecular pathways and targets involved in prostate cancer 
initiation and progression have been identified. Since genetic pathways 
involved in prostate development are frequently reactivated in prostate 
cancer, understanding the role of genes in development can give insight into 
their function in tumourigenesis. 
Pten (Phosphatase and tensin homologue deleted on chromosome 10) is 
frequently mutated in prostate cancer. Correspondingly, adult mice with 
deletions in Pten develop prostate cancer. However the role of Pten in 
prostate development has not been elucidated. 
We have used the conditional Cre-loxP system to delete Pten specifically in 
the mouse prostate epithelia from 17.5 days of embryonic development. 
Loss of Pten at this stage does not affect early prostate formation or 
differentiation into luminal and basal cell types. However, at postnatal day 
7, prostates from Pten mutants exhibit disorganized lumens, increased 
cellular proliferation, and precocious cytodifferentiation. Furthermore, 
upregulation of a target downstream of Pten, phospho-AKT, was also 
observed in Pten mutant prostates.  
These studies suggest that in prostate development, Pten is required for the 
cellular organization of epithelial cells at the stages of lumen formation in 
prostatic ducts. Future work will focus on investigating specific pathways 
affected by Pten loss. The study of Pten in development may therefore yield 
insight into its associated pathways and, by extension, its role in prostate 
cancer and other Pten relevant malignancies. 
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Irreversible cell growth arrest, a process termed cellular senescence, is 
emerging as an intrinsic tumor suppressive mechanism. We have reported 
that acute loss of Pten in vivo promotes the activation of a potent cellular 
senescence response, which we have termed PICS (Pten-loss Induced 
Cellular Senescence) for short. We now show that PICS represents a unique 
form of cellular senescence, distinct from oncogene-induced senescence 
(OIS). The key departure of PICS relative to OIS is characterized by a lack 
of DNA damage response (DDR) and hyper-replication, rendering 
therapeutic enhancement of this process suitable for cancer treatment. 
Further, we have found that PICS is associated with increased p53 
translation. Consistent with these data, preclinical trials in mice show that 
p53-stabilizing drugs potentiated PICS and its tumor suppressive potential. 
Additionally, we demonstrated that pharmacological inhibition of PTEN 
drives senescence and inhibits tumorigenesis in vivo. We are now 
evaluating in mice whether the treatment with DDR-inducing agents may 
cooperate with PICS to further increase p53 levels and in turn enhance the 
senescence response or redirect p53 signaling to apoptosis. Importantly, the 
senescence-enhancing strategies are being tested not only in mice but also 
in a co-clinical manner. This approach, which we have named “The Co-
Clinical Project”, will consist in running pre-clinical trials in appropriate, 
faithful and genetically relevant mouse models in parallel with clinical 
trials. The clinical, biological and pharmacological information (i.e. somatic 
mutational background, germline SNP variations, responsiveness to specific 
regimens, imaging, microarray and proteomics profiles) will be accrued, 
analyzed in parallel and integrated in order to facilitate the identification of 
patient subtypes, key genetic determinants, and biomarkers that predict 
response to specific treatments. 
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Hepatic steatosis and insulin resistance are two important mediators of 
HCV pathogenesis as their clinical impact includes accelerated fibrogenesis 
and reduced response to antiviral therapy. We previously reported that high 
levels of circulating free fatty acids, as observed with obesity and the 
metabolic syndrome, downregulate PTEN expression in hepatocytes via 
mTOR/NFκB/miR-21-dependent mechanisms. PTEN downregulation in 
turn leads to both insulin resistance and steatosis development in 
hepatocytes. Herein, we investigated whether alterations of PTEN 
expression/activity in the liver may mediate also the metabolic changes 
observed in HCV infection.  
Our data indicated that PTEN expression is downregulated in the liver of 
patients infected with HCV genotype 3a at the protein level, without 
significant changes in PTEN mRNA expression, thus suggesting that HCV 
affects PTEN protein stability or degradation. Interestingly, downregulation 
of PTEN protein expression was also triggered in vitro by expressing only 
the HCV core protein of genotype 3a in Huh-7 hepatoma cells. In contrast, 
expression of HCV core protein of genotype 1b had no effect on PTEN 
expression. As expected, the expression of genotype 3a core protein (but not 
1b) induced the appearance of large lipid droplets, while both core proteins 
expression led to a significant decrease of IRS-1, a major contributor to 
insulin resistance mediated by HCV infection. Overexpression of PTEN in 
Huh-7 cells expressing the genotype 3a core protein restored to 
physiological levels the IRS-1 expression, while at the same time prevented 
core 3a-expressing cells from developing steatosis.  
Together, our results suggest that alterations of PTEN expression/activity in 
the context of HCV infection may be involved in the pathogenesis of two 
major metabolic changes induced by HCV, i.e. insulin resistance and 
steatosis. 
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Glioblastoma is an aggressive and heterogeneous astrocytic brain tumor 
characterized by frequent genomic alterations in the PI3K/PTEN, p53 and RB 
signaling pathways. This tumor affects both adults and children, and is 
universally associated with a dismal prognosis. Minimal progress has been 
made towards effective treatments due in part to a lack of clinically relevant 
models of this disease.  
Inducible conditional deletion of Pten in mature astrocytes and their progenitors 
had minimal effects on the activation of downstream effectors of the PI3K 
signaling pathway and resulted in no abnormalities in cell size or proliferation. 
In contrast, deletion of Pten in combination with other glioma tumor 
suppressors generated spontaneous high grade glioma with histological and 
genetic similarity to the human disease. Tumor penetrance and latency 
depended both on the number of tumor suppressors targeted, as well as the 
specific tumor suppressors deleted. Conditional knock-out of three tumor 
suppressor genes, Pten, Trp53 and Rb1 (TKO) resulted in increased tumor 
penetrance and decreased median survival relative to conditional double knock-
out (DKO) combinations involving Trp53. DKO of Pten and Rb1 failed to 
generate intracranial tumors. Tumors generated in each model showed robust 
activation of downstream effectors of the PI3K signaling pathway including 
pAkt and pS6.  
CreER expression in this model was driven by the GFAP promoter and its 
induction in the mature brain targeted primarily mature astrocytes, with some 
activity in proliferative niches of the adult brain. MRI studies showed that the 
tumors preferentially arose within proliferative niches but also in additional 
distinct regions including the cortex, midbrain and cerebellum, suggesting that 
cells outside of the proliferative niche can be susceptible to transformation.  
We further investigated the tumor initiating capability of cells harvested from 
these tumors, by orthotopic transplantation of limiting cell dilutions into 
immunodeficient mice. As few as 100 implanted cells successfully induced 
tumor formation that faithfully recapitulated the histopathological features of 
the original tumor, suggesting that tumor initiating cells represent a substantial 
portion of the tumor cell population.  
The combined deletion of Pten and Trp53 in mature astrocytes and their 
progenitors was sufficient to induce high grade glioma in mice and 
gliomagenesis was potentiated by the additional deletion of Rb1.Resulting 
tumors accurately reflected the heterogeneity, histopathology and genetic 
alterations frequently noted in human disease, and contained a significant 
proportion of cells with tumor initiating activity. 
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Progenitor or cancer stem cells (CSC) are “altered” stem cells with the 
capacity to form tumors. We used a liver specific Pten (phosphatase and 
tensin homologue deleted on chromosome ten) deletion murine model to 
investigate the mechanism of hepatic cancer stem cell activation in vivo. 
We have shown that loss of PTEN induces the transformation of liver 
progenitor cells to cancer stem cells (CSCs). We hypothesize that 
hepatocyte cell death resulting from PTEN loss induced liver steatosis 
presents a selection pressure for mutant progenitor cells to proliferate and 
replace liver parenchyma. We found that hepatic injury is followed by 
expansion of hepatic progenitors and demonstrate that elevated expressions 
of hepatic progenitor cell markers Cytokeratin 19 (CK 19), Epithelial cell 
adhesion molecule (EpCAM), and α-fetoprotein (AFP). We identified 
progenitor cells co-expressing dual lineage markers for hepatocytes and 
cholangiocytes. In addition, tumors developed in the liver specific Pten-null 
mice are also from both lineages: cholangiocellular carcinoma (CC) and 
hepatocellular carcinoma (HCC). The development of tumor, progenitor 
cell proliferation and hepatic injury are all reversed when Akt2, the 
downstream effector of PTEN is deleted in the Pten mutant mice. Here, loss 
of AKT2 did not result in more severe cell death (rather the opposite) or 
reduce progenitor cell proliferation as would be predicted from its pro-
survival and pro-proliferation function. Thus, the major effect of AKT2 is 
likely metabolic regulation and the effect of this metabolic regulation on 
hepatocyte cell death. Concomitantly, we observed diminished steatosis 
occurring with AKT2 loss. Together, our data suggest that PTEN loss 
induces liver cancer development through two processes: inducing the 
transformation of CSCs and promoting the activation of CSCs by inducing 
lipotoxicity in hepatocytes. 
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The tumor suppressor protein p53 is a key mediator of the cellular response 
to DNA damage and TP53 is one of the most frequently mutated genes in 
human cancers. DNA damage induces the accumulation and activation of 
p53, leading to gene expression changes and ultimately causing cell death, 
senesce or cell cycle arrest. p21 is a key effector of the p53/cell cycle arrest 
pathway. In response to DNA damage, p53 activates p21 transcription 
thereby arresting cells in G1 and enforcing S- and G2- cell cycle arrests. 
p21 expression is regulated by additional signaling pathways including 
RAS/MAPK, TGFβ, EGF and IFNγ. To monitor p53-dependent and- 
independent regulation of p21 expression in living animals, knock-in mice 
were generated that express firefly luciferase (FLuc) from the endogenous 
p21Waf1/Cip1 (p21) locus. These mice were also bred with p53 null mice in 
order to monitor p21 promoter activity in the absence of p53. 
Bioluminescence imaging of reporter mice prior to and after exposure to 
etoposide or irinotecan revealed robust activation of the p21 promoter and 
this response was p53-dependent. Experiments performed with MEFs 
derived from reporter embryos verified that activation of the p21 promoter 
by DNA damage is p53-dependent. Interesting p21 expression patterns were 
observed throughout untreated animals. p21 expression was found to be 
highest in the penis, vagina, epididymis, preputial glands, large intestine, 
small intestine, bladder, testes, skeletal muscle, peritoneal fat, pancreas, and 
femur (bone marrow). Little to no expression was observed in mammary 
glands, seminal vesicles, stomach, olfactory bulb, spleen, lungs, liver, 
kidney, heart, salivary glands and brain. Low light microscopy revealed 
bioluminescence with cell-type specificity in various organs including 
discrete regions of the liver, vagina, penis, pancreas, as well as brain. These 
mice are currently being used to address the contribution made by p21 to 
animal homeostasis during nutrient deprivation and chemotherapy. 
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OXIDATIVE STRESS-MEDIATED AMPLIFICATION OF AKT/MTOR 
SIGNALING PATHWAY LEADS TO MYELOPROLIFERATIVE 
SYNDROME IN FOXO3-NULL MICE: A ROLE FOR LNK ADAPTOR 
PROTEIN 
 
Safak Yalcin1, Xin Zhang1, Dragan Marinkovic1, Wei Tong2, Sathish K 
Mungamuri1, Saghi Ghaffari1  
1Mount Sinai School of Medicine, Gene and Cell Medicine, 1425 Madison 
Ave , New York, NY, 10029, 2Children’s Hospital of Philadelphia, 
2Division of Hematology, 3615 Civic Center Blvd., Philadelphia, PA, 
19104 
 
Reactive oxygen species (ROS) participate in normal intercellular signaling 
including the regulation of PI3-kinase signaling via PTEN and in many 
diseases including cancer and aging although the associated mechanisms are 
not fully understood. Balanced regulation of oxidative stress is critical for 
maintenance of hematopoietic stem cells. Forkhead Box O (FoxO) 3 of 
FoxO transcription factors is a downstream target of PI3-kinase/AKT 
signaling pathway that is critical for the regulation of ROS concentrations in 
many cell types. FoxO3 redox modulation is essential for maintenance of 
hematopoietic stem cells in both young (Yalcin et al., 2008) and old 
(Miyamoto et al., 2007) mice. However the role of FoxO in the regulation 
of hematopoietic progenitors is not clear. Here we show that loss of FoxO3 
causes a myeloproliferative syndrome with splenomegaly and increased 
hematopoietic progenitors that are hypersensitive to cytokines in mice. The 
expansion of hematopoietic progenitors in FoxO3-/- mice does not appear 
to be mediated by activation of their hematopoietic stem cell compartment, 
since FoxO3-/- hematopoietic stem cells are delayed in their cycling at the 
G2/M phase, and FoxO3-/- hematopoietic stem cells do not generate an 
increased number of hematopoietic progenitors in vitro (Yalcin et al., 2008). 
However, analysis of mutant hematopoietic progenitors found that these 
cells contain increased ROS. Accumulation of ROS in FoxO3-/- mice 
results in expansion of primitive myeloid progenitor compartment via 
activation of the AKT/mTOR signaling pathway but not STAT5 and results 
in relative deficiency of Lnk, a negative regulator of cytokine signaling. 
Accordingly, In vivo treatment with ROS scavenger N-acetyl-cysteine 
(NAC) corrects these biochemical abnormalities and relieves the 
myeloproliferation. In addition, enforced expression of Lnk by retroviral 
transfer corrects the abnormal expansion of FoxO3-/- hematopoietic 
progenitors in vivo. Moreover, in vivo administration of the mTOR 
inhibitor rapamycin results in significant reduction of FoxO3-/--derived 
primitive myeloid progenitor CFU-Sd12 as compared to controls in lethally 
irradiated hosts. In agreement with these results, FoxO3 but not other 
FoxOs is mostly found in the nucleus of primitive myeloid progenitors 
suggesting that FoxO3 is the principal FoxO operating in these cells. Our 
combined results show that loss of FoxO3 causes increased ROS 
accumulation in hematopoietic progenitors. In turn, this inhibits Lnk 
expression that contributes to exaggerated cytokine responses that lead to 
myeloproliferation. 
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MAMMALIAN TARGET OF RAPAMYCIN REGULATES CELL 
DIFFERENTIATION THROUGH THE STAT3-P63-JAGGED-NOTCH 
CASCADE 
 
Jianhui Ma1, Huangxuan Shen2, Xinxin Chen1, Haiyong Peng1, Qian Sun1, 
Xiaojun Zha1, Fang Wang1, Ying Wang1, Shu Zhang1, Lizi Wu3, David J 
Kwiatkowski,4, Hongbing Zhang1 
1Chinese Academy of Medical Sciences and Peking Union Medical College, 
Department of Physiology, 5 Dong Dan San Tiao, Beijing, 100005, China, 
2Sun Yat-Sen University, State Key Laboratory of Ophthalmology, 
Laboratory of Ocular Genetics, Zhongshan Ophthalmic Center, Guangzhou 
, 510060, China, 3Shands Cancer Center, University of Florida, Department 
of Molecular Genetics and Microbiology, 1376 Mowry Road, Gainesville, 
FL, 32610, 4 Brigham and Women's Hospital, Harvard Medical School, 
Division of Translational Medicine, Department of Medicine, 1 Blackfan 
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The receptor tyrosine kinase (RTK)-PI3K-AKT-mammalian target of 
rapamycin (mTOR) pathway is frequently altered in cancer, but the 
underlying mechanism leading to tumorigenesis by activated mTOR 
remains less clear. Here, we have shown that mTOR is a positive regulator 
of Notch signaling in mouse and human cells, acting through induction of 
the STAT3-p63-Jagged signaling cascade. Furthermore, in response to 
differential cues from mTOR, we found that Notch serves as a molecular 
switch to shift the balance between cell proliferation and differentiation. We 
determined that hyperactive mTOR signaling impaired cell differentiation 
of murine embryonic fibroblasts, via potentiation of Notch signaling. 
Elevated mTOR signaling strongly correlated with enhanced Notch 
signaling in poorly differentiated but not in well-differentiated human breast 
cancers. Both human lung lymphangioleiomyomatosis (LAM) and mouse 
kidney tumors with hyperactive mTOR due to tumor suppressor TSC1 or 
TSC2 deficiency exhibited enhanced STAT3-p63-Notch signaling. 
Furthermore, tumorigenic potential of cells with uncontrolled mTOR 
signaling was suppressed by Notch inhibition. Our data therefore suggest 
that perturbation of cell differentiation by augmented Notch signaling could 
be responsible for the under-differentiated phenotype displayed by certain 
tumors with an aberrantly activated RTK-PI3K-AKT-mTOR pathway. 
Additionally, the STAT3-p63-Notch axis may be a useful target for the 
treatment of cancers exhibiting hyperactive mTOR signaling. 
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THE LKB1/AMPK TUMOR SUPPRESSOR PATHWAY 
COORDINATES CELL GROWTH AND METABOLISM 
 
Reuben J Shaw  
Salk Institute for Biological Studies, Molecular and Cell Biology 
Laboratory, Howard Hughes Medical Institute, La Jolla, CA, 92037 
 
The serine/threonine kinase LKB1 is a tumor suppressor gene mutated in 
the familial cancer condition Peutz-Jeghers syndrome (PJS), as well as in 
30% of sporadic non-small cell lung cancer (NSCLC). One of the critical 
substrates of LKB1 is the AMP-activated protein kinase (AMPK). AMPK is 
a highly conserved sensor of cellular energy status found in all eukaryotic 
cells. Using a proteomic and bioinformatics approach, we identified the 
mTOR-binding subunit raptor as a critical substrate of AMPK mediating its 
effects on growth control. AMPK directly phosphorylates the mTOR 
binding partner raptor on two serine residues that are conserved throughout 
eukaryotes, and this phosphorylation induces 14-3-3 binding to raptor. 
Phosphorylation of raptor by AMPK is required for the inhibition of 
mTORC1 and for cell cycle arrest following energy stress. More recently 
we have found additional connections between AMPK, mTOR and control 
of autophagy. Collectively, these studies have uncovered novel conserved 
effectors of AMPK that mediates its role as a metabolic checkpoint 
coordinating cell growth with energy status. These findings suggest a 
possible therapeutic window for treatment of tumors bearing loss of TSC or 
hyperactivation of mTOR by other genetic lesions with AMPK agonists. In 
addition, the AMPK-raptor connection reinforces the idea that LKB1-
deficient tumors such as those arising in PJS patients and sporadic NSCLC 
may be uniquely sensitive to rapamycin analogs, which we have recently 
explored in preclinical trials in LKB1 heterozygous mice. We have found 
that hamartomas in LKB1+/- mice exhibit functional increases in glucose 
metabolism as visualized by FDG-PET, which is suppressed by rapamycin 
treatment. HIF-1a and HIF-1a target genes including GLUT1 and 
Hexokinase2 are upregulated in LKB1-dependent tumors providing a 
molecular explanation for the increased FDG-PET and rapamycin 
sensitivity. More recently in a K-ras, LKB1 mutant mouse model of 
NSCLC we have also observed deregulation of mTOR and HIF signaling. 
The connection between LKB1, AMPK, and mTOR signaling further 
illustrates molecular connections underlying the development of both 
cancer and metabolic syndrome. 
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ACTIVATION OF A METABOLIC GENE REGULATORY NETWORK 
DOWNSTREAM OF MTORC1 
 
Katrin Duvel1, Jessica L Yecies1, Suchithra Menon1, Clary B Clish2, Leon O 
Murphy3, Brendan D Manning1  
1Harvard School of Public Health, Genetics and Complex Diseases, 665 
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The mammalian target of rapamycin complex 1 (mTORC1) has the ability 
to sense and integrate signals from a variety of sources, including 
intracellular nutrients and energy, growth factors, and cellular stresses. Over 
the past eight years, the collective work of several laboratories has found 
that mTORC1 senses many of these signals through a small G protein 
switch involving the tuberous sclerosis complex (TSC) tumor suppressors, 
TSC1 and TSC2, and the Ras-related small G protein Rheb. Multi-site 
phosphorylation of the TSC2 protein downstream of distinct signaling 
pathways appears to account for much of mTORC1’s signal-integrating 
capacity. Importantly, Akt/PKB-dependent phosphorylation and inhibition 
of TSC2 activates mTORC1, and this represents a major downstream event 
driving both physiological and pathological responses to PI3K signaling. 
 
Aberrant regulation of the mammalian target of rapamycin complex 1 
(mTORC1) is a common molecular event in a large variety of pathological 
settings, including genetic tumor syndromes and cancer, obesity and type-2 
diabetes, and both childhood and aging-related neurological disorders. 
Many of the genetic and environmental factors contributing to these 
diseases affect the signaling network that converges on the TSC1-TSC2 
complex. However, the downstream consequences of mTORC1 activation 
remain poorly defined. Here, we take advantage of genetic settings with loss 
of the TSC1-TSC2 complex to constitutively activate mTORC1 signaling in 
a manner that isolates it from upstream pathways. Through a combination 
of unbiased genomic, metabolomic, and bioinformatic approaches, we 
demonstrate that mTORC1 activation is sufficient to stimulate specific 
metabolic pathways, including glycolysis, the pentose phosphate pathway, 
and de novo lipid biosynthesis. This is achieved through the activation of a 
transcriptional program affecting metabolic gene targets of hypoxia-
inducible factor 1 alpha (HIF1α) and sterol regulatory element-binding 
protein 1 and 2 (SREBP1 and SREBP2). While HIF1α stimulates 
glycolysis, SREBP1 and 2 induce both the oxidative arm of the pentose 
phosphate pathway and lipid biosynthesis and are required for the growth 
factor-independent proliferation of TSC gene-deficient cells downstream of 
mTORC1. Therefore, we demonstrate that, in addition to promoting protein 
synthesis, mTORC1 activation is sufficient to promote specific bioenergetic 
and anabolic processes that are likely to contribute to the 
pathophysiological properties of a diverse array of diseases. 
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INTEGRATION OF AMINO ACID AND GLUCOSE SIGNALING IN 
MTOR COMPLEX 1 (MTORC1)-DEPENDENT REGULATION OF 
CELL GROWTH AND SURVIVAL. 
 
John Blenis, Andrew Y Choo, Sang Gyun Kim, Greg R Hoffman, Neil 
Kubica, Sarah J Mahoney  
 
Harvard Medical School, Cell Biology, 240 Longwood Ave., Boston, MA, 
02115 
 
Inappropriate activation of mTORC1 signaling pathways contributes to 
altered cellular metabolism and growth in a variety of human disorders 
including benign tumor syndromes like LAM and tuberous sclerosis (TSC), 
most malignancies, diabetes, heart disease and obesity. Mechanisms by 
which amino acids and glucose regulate the pathway to drive cell growth, 
and how specific amino acids can also promote cancer cell survival when 
the pathway is inhibited (drug resistance), will be discussed. 
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THE LATE ENDOSOME IS ESSENTIAL FOR mTORC1 SIGNALING 
 
Rory J Flinn1, Ying Yan1, Sumanta Goswami2, Peter J Parker3, Jonathan M 
Backer1  
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The multi-subunit mTORC1 complex integrates signals from growth factors 
and nutrients to regulate protein synthesis, cell growth, and autophagy. 
Significant evidence suggests that TOR is regulated by and/or regulates 
various aspects in the endocytic system. To examine how endocytic 
trafficking might be involved in nutrient regulation of mTORC1, we 
perturbed specific endocytic trafficking pathways and measured mTORC1 
activity using S6K1 as a readout. When early/late endosomal conversion 
was blocked by either overexpression of constitutively active Rab5 
(Rab5CA) or knockdown of the Rab7 GEF hVps39, insulin and amino acid 
stimulated mTORC1/S6K1 activation were inhibited and mTOR localized 
to hybrid early/late endosomes. Inhibition of other stages of endocytic 
trafficking had no effect on mTORC1. Overexpression of Rheb, which 
activates mTOR independently of mTOR localization, rescued mTORC1 
signaling in cells expressing Rab5CA, whereas hyperactivation of 
endogenous Rheb in TSC2-/- MEFs did not. These data suggest that 
integrity of late endosomes is essential for amino acid- and insulin-
stimulated mTORC1 signaling, and that blocking the early/late endosomal 
conversion prevents mTOR from interacting with Rheb in the late 
endosomal compartment. 
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FOXOS SERVE AS AN ENERGY STRESS CHECKPOINT AND 
SUPPRESS MTORC1-MEDIATED RENAL CANCER DEVELOPMENT 
 
Boyi Gan1, Carol Lim1, Gerald Chu1,2, Sujun Hua1, Zhihu Ding1, Jian Hu1, 
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The mammalian target of rapamycin complex 1 (mTORC1) has recently 
been identified as an important therapeutic target for renal cell carcinoma 
(RCC). The effective clinical application of mTORC1 targeted therapy in 
RCC would be enabled by knowledge of the key downstream effector(s) of 
mTORC1 activation and the nature and role of mTORC1-mediated negative 
feedback signaling in RCC. Here, utilizing the conditional TSC1 knockout 
(KO) mouse as an mTORC1 hyper-activation-driven renal cancer model 
system, we show that FoxO1 and FoxO3 are robustly activated in TSC1 
deficient benign polycystic neoplasias, but consistently extinguished with 
progression to renal adenomas and carcinomas. In addition, relative to the 
TSC1-null model, combined deletion of TSC1 and FoxO1/3/4 provoked 
dramatic exacerbation of the renal tumor phenotypes, establishing activated 
FoxO signaling as a potent block in TSC1-null renal cancer development. 
Mechanistically, we show that FoxO activation initiated by mTORC1 
hyper-activation functions to induce apoptosis in response to energy stress. 
In line with these murine data, we found that FoxO activation serves to 
promote energy stress-induced apoptosis in human renal cancer cells and 
that FoxOs are extinguished in the majority of human clear cell and 
papillary renal tumor samples compared with more benign types of RCC 
including chromophobe and oncocytoma. Further integrated transcriptomic, 
computational and functional studies identified Myc-Mxi1 signaling as the 
key downstream effector of FoxOs in the regulation of renal tumorigenesis. 
Together, our data identify FoxOs as novel tumor suppressors in the 
progression to renal cancer and analysis of the FoxO-regulated 
transcriptional network reveals a metabolic stress checkpoint functioning to 
constrain mTORC1-mediated renal tumorigenesis. 
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“MTOR AND THE CONTROL OF GROWTH” 
 
David M Sabatini  
Whitehead Institute, Sabatini Lab, Nine Cambridge Center, Cambridge, 
MA, 02142 
 
mTOR is the target of the immunosuppressive drug rapamycin and the 
central component of a nutrient- and hormone-sensitive signaling pathway 
that regulates cell growth and proliferation. We now appreciate that this 
pathway becomes deregulated in many human cancers and has an important 
role in the control of metabolism and aging. We have identified two distinct 
mTOR-containing proteins complexes, one of which regulates growth 
through S6K and another that regulates cell survival through Akt. These 
complexes, mTORC1 and mTORC2, define both rapamycin-sensitive and 
insensitive branches of the mTOR pathway. I will discuss new results from 
our lab on the regulation and functions of the mTORC1 and mTORC2 
pathways.  
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FORKHEAD PROTEINS IN INSULIN ACTION 
 
Domenico Accili  
Columbia University, Department of Medicine, 1150 St. Nicholas. Ave., 
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Regulation of PTEN signaling downstream of Akt is important for 
metabolic homeostasis at the cellular and organismal levels. Foxo 
transcription factors are key Akt substrates that mediate growth factor and 
nutrient signaling to regulate diverse cellular processes, including 
metabolism, growth, and differentiation. Studies in our laboratory have 
focused on the mechanism by which Foxo proteins affect metabolism and 
cellular differentiation. We have shown that Foxo1 is an insulin-regulated 
transcription factor. Our studies have demonstrated that Foxo1 is a key 
effector of insulin action in several tissues: liver, where it controls insulin 
inhibition of glucose production and stimulation of lipid synthesis; 
pancreatic β-cells, where it controls proliferation and differentiation; pre-
adipocytes, where it controls insulin-dependent differentiation; myoblasts, 
where it controls myotube formation; and brain, where it controls food 
intake through its ability to regulate expression of peptidases required for 
neuropeptide processing. Thus, regulation of Foxo1 function can potentially 
affect insulin sensitivity in vivo by regulating various aspects of fuel 
metabolism. Foxo1 activity is regulated by post-translational modifications 
that include, but are not limited to, phosphorylation and acetylation. Using 
an allelic series of knock-in mice with mutations in the acetylation sites and 
DNA binding domain of Foxo1, we have begun to systematically dissect 
how these modifications affect metabolism and cellular responses to altered 
nutrient availability. The findings reveal a range of novel biochemical and 
genetic pathways that can be affected by Foxo1 in response to changes in 
the metabolic status of the organism. 
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SYSTEMS BIOLOGY APPROACH TO PERSONALIZED MEDICINE. 
 
Gordon B Mills  
U.T. M. D. Anderson Cancer Center, Systems Biology, 1515 Holcombe 
Blvd., Unit 950, Houston, TX, 77030 
 
The realization of the promise of personalized molecular medicine will 
require the efficient development and implementation of novel targeted 
therapeutics. The goal will be to deliver the right drug to the right patient at 
the right time at the right dose. This effort will require a integration of 
information from the DNA, RNA and protein level into predictors of which 
patients are likely to benefit from particular therapies. The overall 
likelihood of response to particular drugs represents the interaction between 
predictors of sensitivity with predictors of resistance. This session will use 
examples with predictors from the DNA RNA and protein level to illustrate 
some of the opportunities and challenges to the implementation of 
personalized medicine. It will demonstrate the need to integrate information 
from multiple technological platforms into visualizable pathways and 
networks as a key step in the process.  
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THE MTOR PATHWAY IN CANCER: MECHANISMS AND 
THERAPEUTIC PROMISE 
 
Karen Cichowski  
BWH/Harvard Medical School, Genetics, 458c NRB, 77 Avenue Louis 
Pasteur, Boston, MA, 02115 
 
Aberrant activation of TORC1 is triggered by the loss of several tumor 
suppressors, including PTEN, and is thought to be one of the signals that 
promote cancer. However the ultimate downstream target proteins that 
mediate tumorigenesis are largely unknown. Moreover it is not currently 
clear whether we will be able to effectively harness the therapeutic potential 
of mTOR inhibitors for treating human tumors. Utilizing cell biological, 
biochemical and mouse modeling approaches we have identified a critical 
downstream target of the mTOR pathway in our tumor model. Notably, its 
expression is potently suppressed by mTOR inhibitors and its re-expression 
accompanies resistance to these agents. However we have also been 
utilizing mTOR inhibitors as a platform for rationally developing 
combination therapies and have identified agents that together promote 
dramatic tumor regression in vivo in genetically engineered mouse models 
(GEMMs). The implications for these findings and the specific utility of 
GEMMs in these studies will be discussed in the context of tumor-types 
driven by hyperactivation of the mTOR pathway. 
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PRECLINICAL EVIDENCE SUPPORTING COMBINATION 
PARTNERS FOR NVP-BEZ235 BREAST CANCER TRIALS. 
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NVP-BEZ235 is a dual PI3K/mTOR inhibitor currently in phase I clinical 
trials. In a former study we have shown that NVP-BEZ235 selectively 
induced cell death in breast cancer cell lines harboring either HER2 
amplification and/or PIK3CA mutation, but not in lines with PTEN LOF or 
K-RAS mutation (poster Irmgard Hofmann). Here, we show that NVP-
BEZ235 efficiently shuts down the PI3K pathway (AktS473P / S6P) in all 
HER2 amplified and/or PIK3CA mutated lines. In contrast, the HER1/2 
inhibitor lapatinib could only efficiently inhibit the PI3K pathway in a 
subset of these lines which were characterized by high HER3 
phosphorylation levels causing strong PI3K recruitment to HER2/HER3. 
Hence, in HER2 amplified tumors anti-HER2/HER3 agents are expected to 
display synergistic activities with NVP-BEZ235 treatment.  
In the HER2 amplified and/or PIK3CA mutated breast cancer cell lines the 
ribosomal S6 S235/236 sites were more sensitive to NVP-BEZ235 
treatment than in lines with PTEN LOF or K-RAS mutation while the 
ribosomal S6 S240/244 sites were equally responsive across the panel. In 
addition, the lines with PTEN LOF or K-RAS mutation exhibited higher 
MAPK phosphorylation than the HER2 amplified and/or PIK3CA mutated 
lines. Therefore, in breast cancer lines PTEN LOF might result in redundant 
phosphorylation of the mTORC1 downstream effecter RPS6 by the ERK 
pathway and hence incomplete pathway shut down by NVP-BEZ235. 
Therefore, breast cancer patients with loss of PTEN function might benefit 
from a combination of NVP-BEZ235 with a MEK inhibitor.  
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Most of the cancer-specific mutations in p110α (PIK3CA) occur in hotspots 
located in the helical and kinase domains. Helical and kinase domain 
mutations induce gain of function by different molecular mechanisms. The 
E542K and E545K helical domain mutations result in independence from 
binding to the regulatory subunit p85 and mimic activation of the enzyme 
by upstream signaling. To be active, these mutants still require binding to 
Ras. The kinase domain mutation H1047R can function in the absence of 
Ras binding. This mutation appears to induce a conformational change that 
mimics activation of the enzyme by Ras. The dependence of H1047R on 
p85 binding may be explained by the contacts between residues of the inter-
SH2 domain of p85 and the kinase domain of p110α. 
The glioblastoma-derived mutants of p85α induce oncogenic cellular 
transformation as single oncogenes in cultures of avian cells. The 
efficiencies of transformation vary greatly between different mutants. All 
these mutant p85α proteins still bind to p110 and induce elevated levels of 
downstream signaling. Their sensitivities to isoform-specific inhibitors of 
p110 suggest that most of the oncogenic activity seen with these mutants 
requires interaction with p110α, and a minor portion relies on interaction 
with p110β. The p110γ and p110δ isoforms do not participate in the 
transformation of cultured cells by the glioblastoma-derived mutants of 
p85α. 
 
This work was supported by grants from the National Cancer Institute. 
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ROLE OF FOXO TRANSCRIPTION FACTORS IN AGING 
 
Anne Brunet  
Stanford University School of Medicine, Genetics, 300 Pasteur Drive, 
Stanford, CA, 94305 
 
Aging is regulated by modifications in single genes and by simple changes 
in the environment. The signaling pathway connecting insulin, PI3K, Akt, 
and FOXO transcription factors integrate environmental stimuli to regulate 
lifespan. FOXO transcription factors are directly phosphorylated in 
response to insulin/growth factor signaling by the protein kinase Akt, 
thereby causing their sequestration in the cytoplasm. In the absence of 
insulin/growth factors, FOXO factors translocate to the nucleus where they 
trigger a range of cellular responses, including resistance to oxidative stress, 
a phenotype highly coupled with lifespan extension. FOXO factors integrate 
oxidative stress stimuli via phosphorylation and acetylation of specific 
residues. Oxidative stress stimuli elicit the physical interaction between 
FOXO and SIRT1 deacetylase, a member of the Sir2 family, which extend 
longevity in invertebrates. Our recent results indicate that FOXO 
transcription factors are also regulated in response to nutrient deprivation by 
the energy-sensing AMP-dependent protein kinase (AMPK) pathway. 
AMPK phosphorylation enhances FOXO transcriptional activity, leading to 
the expression of specific target genes involved in stress resistance and 
changes in energy metabolism. The AMPK pathway plays a crucial role in 
the ability of a dietary restriction regimen to extend lifespan in worms. 
Understanding the intricate signaling networks that translate environmental 
conditions into changes in gene expression that extend lifespan will be of 
critical importance to identify ways to delay the onset of aging and age-
dependent diseases. 
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CRTC-1 - A NOVEL CALCINEUIN AND AMPK TARGET FOR 
LIFESPAN EXTENSION IN C. ELEGANS 
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Many interventions that extend lifespan do so by reducing costly energetic 
activities such as translation, growth and reproduction. A key example is 
AMP-activated protein kinase (AMPK), which down-regulates energy 
requiring processes when energy intake is low. Recent studies have shown 
that C. elegans expressing gain of function (GOF) AMPK transgenes are 
long-lived, and that AMPK is critical for the longevity of dauer larvae. 
Conversely, loss of function (LOF) of the protein phosphatase Calcineurin 
extends C. elegans lifespan.  
 
We show here that AMPK and Calcineurin phosphorylate and 
dephosphorylate the worm CREB-regulated transcription co-activator 
(CRTC-1) respectively. Phosphorylation of CRTC-1 results in its 
deactivation and retention in the cytosol in a 14-3-3 dependent manner. 
AMPK GOF or Calcineurin LOF both result in CRTC-1 cytosolic 
translocation. Site-specific mutation of two conserved AMPK target 
residues on CRTC-1 from serine to alanine renders CRTC-1 constitutively 
nuclear. Calcineurin LOF robustly extends the lifespan of worms over-
expressing wild type CRTC-1 but has no effect when CRTC-1 is 
constitutively in the nucleus.  
 
In mammals CRTC family members bind to the transcription factor CREB, 
promoting transcription of its target genes. CREB has critical functions 
ranging from memory formation to glucose homeostasis. We show that 
down-regulation of CRTC-1, CREB and a subset of CREB target genes also 
extend lifespan.  
 
We therefore propose that the lifespan effects of AMPK and Calcineurin are 
mediated at least in part via reducing the activity of CREB and its target 
genes via inactivation of the key CREB coactivator, CRTC-1.  
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Our laboratory is interested in the mechanistic connections between cancer 
and aging. For this, we have generated a number of genetically-modified 
mice with increase gene dosage of relevant tumor suppressors, such as p53 
and Ink4a/Arf. The lipid phosphatase PTEN is another critical tumor 
suppressor that counteracts the effects of growth factors and hormones by 
constitutively decreasing the levels of the second-messenger lipid PIP3 
thereby inhibiting the metabolic sensor mTOR. Moderate inhibition of the 
mTOR pathway is beneficial for aging, although the physiological 
processes implicated remain poorly understood. Here, we have generated 
transgenic mice with a modest global increase in PTEN activity. PTENtg 
mice show a remarkable improvement in healthy aging and a significant 
extension in longevity. We will present a detailed analysis of these mice and 
WILL PROPOSE NOVEL CONNECTIONS BETWEEN CANCER AND 
AGING. 
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Biological outputs of insulin/IGF signaling are regulated through essential 
mediators, such as IRSs, PI3-kinase, and PKB/Akt. These mediators serve 
critical roles in signal propagation, feedback, and as junctions for crosstalk 
with other pathways. Abnormal insulin/IGF signaling results in disease, 
such as obesity, diabetes, and cancer. Given the vital role of this signaling 
pathway to human health, unraveling its regulatory mechanisms is crucial. 
Components of this pathway are highly conserved throughout evolution. 
PTEN, one of the well-defined regulators of this pathway, functions as a 
lipid phosphatase that negatively regulates insulin/IGF signaling at the PIP3 
level that is upregulated by activated PI3-kinase in both Drosophila and 
mammals. To discover genetic modulators of PTEN in Drosophila, we 
performed a loss-of-function genetic screen seeking the molecules that 
modify the phenotype elicited by PTEN overexpression in the Drosophila 
eye. From the screen, we identified a member of the Dbl-family, 
DRhoGEF2, a guanine nucleotide exchange factor, suppresses PTEN-
overexpression eye phenotype via its effects on dPKB/dAkt activation. 
From a genetic rescue, we established that PDZ-RhoGEF, a member of the 
regulator of G-protein signal (RGS)-like domain containing Rho GEFs 
(RGS-RhoGEFs) subfamily of Dbl-family GEFs, is the closest mammalian 
counterpart of DRhoGEF2. PDZ-RhoGEF is essential for cell proliferation 
and survival through ROCK-dependent activation of IRS/PI3-kinase 
signaling cascade, which has a major impact on adipose tissue homeostasis. 
Through an integrative approach, we have demonstrated that 
DRhoGEF2/PDZ-RhoGEF-dependent signaling has tissue-specific effects 
on insulin/IGF-signaling throughput in both Drosophila and mammals. 
Taken together, our results implicate PDZ-RhoGEF as a major 
physiological modulator of insulin/IGF-1 signaling and a key factor in 
adipose tissue biology. Particularly, the role of PDZ-RhoGEF in diet related 
pathological outcome provides an alternative therapeutic opportunity in 
disease intervention.  
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VISITOR INFORMATION 
 
EMERGENCY                CSHL                          BANBURY 
Fire (9) 742-3300 (9) 692-4747 
Ambulance (9) 742-3300 (9) 692-4747 
Poison (9) 542-2323 (9) 542-2323 
Police (9) 911 (9) 549-8800 
Safety-Security Extension 8870  
 
Emergency Room 
Huntington Hospital 
270 Park Avenue, Huntington 
631-351-2300 
(1037)  
Dentists 
Dr. William Berg 
Dr. Robert Zeman 
 
631-271-2310 
631-271-8090 
Doctor 
MediCenter 
234 W. Jericho Tpke., Huntington Station 
631-423-5400 
(1034) 
Drugs - 24 hours, 7 days 
Rite-Aid 
391 W. Main Street, Huntington 
631-549-9400 
(1039) 
Free Speed Dial 
Dial the four numbers (****) from any tan house phone to place a 
free call. 
GENERAL INFORMATION 
 
Books, Gifts, Snacks, Clothing, Newspapers 
 BOOKSTORE   367-8837 (hours posted on door) 
 Located in Grace Auditorium, lower level. 
 
Photocopiers, Journals, Periodicals, Books, Newspapers 
 Photocopying – Main Library 
 Hours:  8:00 a.m. – 9:00 p.m. Mon-Fri 
             10:00 a.m. – 6:00 p.m. Saturday 
Helpful tips - Obtain PIN from Meetings & Courses Office  
to enter Library after hours.  See Library staff for photocopier 
code. 
 
Computers, E-mail, Internet access 
 Grace Auditorium 
 Upper level: E-mail only 
 Lower level: Word processing and printing. 
 STMP server address: mail.optonline.net 
 To access your E-mail, you must know the name of your  
 home server.    
 
Dining, Bar 
 Blackford Hall 
  Breakfast  7:30–9:00, Lunch 11:30–1:30, Dinner  5:30–7:00 
  Bar  5:00 p.m. until late  
 Helpful tip - If there is a line at the upper dining area, try the  
 lower dining room 
 
 
 
Messages, Mail, Faxes 
 Message Board, Grace, lower level 
 
Swimming, Tennis, Jogging, Hiking 
June–Sept. Lifeguard on duty at the beach. 12:00 noon–6:00 p.m.  
Two tennis courts open daily. 
 
Russell Fitness Center 
 Dolan Hall, west wing, lower level 
 PIN#:  Press 64305 (then enter #) 
 
Concierge 
 On duty daily at Meetings & Courses Office. 
After hours – From tan house phones, dial x8870 for 
assistance 
  
Pay Phones, House Phones 
Grace, lower level; Cabin Complex; Blackford Hall; Dolan Hall, 
foyer  
 
CSHL’s Green Campus 
 
Cold Spring Harbor Laboratory is pledged to operate in an 
environmentally responsible fashion wherever possible.  In the past, 
we have removed underground oil tanks, remediated asbestos in 
historic buildings, and taken substantial measures to ensure the 
pristine quality of the waters of the harbor. Water used for irrigation 
comes from natural springs and wells on the property itself.  Lawns, 
trees, and planting beds are managed organically whenever possible.  
And trees are planted to replace those felled for construction 
projects.   
 
Two areas in which the Laboratory has focused recent efforts have 
been those of waste management and energy conservation.  The 
Laboratory currently recycles most waste.  Scrap metal, electronics, 
construction debris, batteries, fluorescent light bulbs, toner cartridges, 
and waste oil are all recycled.  For general waste, the Laboratory uses 
a “single stream waste management” system, removing recyclable 
materials and sending the remaining combustible trash to a 
cogeneration plant where it is burned to provide electricity, an 
approach considered among the most energy efficient, while providing 
a high yield of recyclable materials. 
 
Equal attention has been paid to energy conservation.  Most lighting 
fixtures have been replaced with high efficiency fluorescent fixtures, 
and thousands of incandescent bulbs throughout campus have been 
replaced with compact fluorescents.  The Laboratory has also 
embarked on a project that will replace all building management 
systems on campus, reducing heating and cooling costs by as much 
as twenty-five per cent. 
 
Cold Spring Harbor Laboratory continues to explore new ways in 
which we can reduce our environmental footprint, including 
encouraging our visitors and employees to use reusable containers, 
conserve energy, and suggest areas in which the Laboratory’s efforts 
can be improved. This book, for example, is printed on recycled 
paper. 
                       1-800 Access Numbers 
 
 AT&T  9-1-800-321-0288 
 MCI  9-1-800-674-7000 
 
Local Interest 
 Fish Hatchery   631-692-6768 
 Sagamore Hill   516-922-4447 
 Whaling Museum   631-367-3418 
 Heckscher Museum  631-351-3250 
 CSHL DNA Learning  x 5170 
   Center 
 
New York City 
 Helpful tip - 
 Take Syosset Taxi to Syosset Train Station 
 ($8.00 per person, 15 minute ride), then catch Long Island  
 Railroad to Penn Station (33rd Street & 7th Avenue).   
 Train ride about one hour. 
 
   TRANSPORTATION 
Limo, Taxi 
 Syosset Limousine  516-364-9681  (1031) 
 Super Shuttle  800-957-4533  (1033) 
  To head west of CSHL - Syosset train station 
  Syosset Taxi  516-921-2141  (1030) 
 To head east of CSHL - Huntington Village  
  Orange & White Taxi 631-271-3600  (1032) 
Executive Limo  631-696-8000  (1047) 
 
Trains 
 Long Island Rail Road   822-LIRR  
 Schedules available from the Meetings & Courses Office. 
 Amtrak   800-872-7245 
 MetroNorth   800-638-7646 
 New Jersey Transit  201-762-5100 
 
Ferries 
 Bridgeport / Port Jefferson 631-473-0286 (1036) 
 Orient Point/ New London 631-323-2525 (1038) 
 
Car Rentals 
 Avis   631-271-9300 
 Enterprise   631-424-8300 
 Hertz   631-427-6106 
  
Airlines 
 American   800-433-7300 
 America West  800-237-9292 
 British Airways  800-247-9297 
 Continental   800-525-0280 
 Delta   800-221-1212 
 Japan Airlines  800-525-3663 
 Jet Blue   800-538-2583 
 KLM   800-374-7747 
 Lufthansa   800-645-3880 
 Northwest   800-225-2525 
 United   800-241-6522 
 US Airways   800-428-4322 
